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ABSTRACT
Metastatic melanoma is the third most common cancer in Australia with global incidence
increasing. After decades without effective systemic treatments for advanced melanoma, the
advent of targeted and immune therapies has substantially improved patient survival. While
this is encouraging, further research is needed as the majority of patients treated with targeted
therapy ultimately develop drug resistance. Immunotherapy can achieve durable responses in
many patients however, not all patients respond to current single or a combination of immune
checkpoint inhibitors. Considering the cost and potential toxicities to patients being treated
with these therapies, there is an urgent need to develop biomarkers that can predict patient
response to treatment, likelihood of toxicity, and ultimately survival.
Extracellular vesicles (EVs) are small particles that contain a diverse array of molecular cargos
that represent the cell of origin. EVs have established roles in various hallmarks of cancer,
including the mediation of drug resistance and immunosuppression. In addition, EVs have
tremendous potential as biomarkers to predict or monitor patient outcomes. This thesis aims to
provide a foundation of methodologies to explore the potential of melanoma derived EVs. In
turn, this will allow an expansion of our understanding on the role of melanoma derived EVs
on therapeutic outcomes. Chapter 1 of the thesis provided a review into the development of
melanoma, current treatment strategies, drug resistance and a broad introduction on EVs.
Chapter 2 demonstrated the ability to detect the mRNA of BRAF splicing variants in the plasma
of melanoma patients who developed resistance to targeted therapy. Further, it showed that
these mRNA variants were detected in plasma derived EVs. In Chapter 3, the potential of EVs
to transfer resistance to BRAF inhibition was explored utilising a panel of BRAF treatmentresistant cell lines. However, no evidence was found that EVs could transfer BRAF resistance.
In Chapter 4, the plasma of melanoma patients being treated with pembrolizumab was used to
isolate EV-RNA to identify a transcriptional signature predictive of response.
Lastly, Chapter 5 provides a general discussion of the studies presented in this thesis.
Altogether, the results of these studies underscore the potential of EVs as unique biomarkers
to predictive response to treatment in melanoma.
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CHAPTER 1:
General Introduction and Literature Review
This Chapter includes parts from the following manuscript in section 1.4, which has now been
published in Biochemica Biophysica Acta – General Subjects, entitled Resistance
mechanisms to targeted therapy in BRAF-mutant melanoma - a mini review.

As co-author, I wrote the acquired resistance section of the manuscript, reviewed the entire
document, and approved the final submitted version
Authors: Lokeswari P. Tangella1, Michael E. Clark1, Elin S. Gray1
1

School of Medical and Health Sciences, Edith Cowan University, Perth, WA, Australia
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1.0 Introduction to melanoma
Melanoma is the 3rd most common cancer in Australia [1]. Globally 351,880 cases of
melanoma were diagnosed in 2015, resulting in 59,782 cancer-related deaths [2]. Melanoma
incidence by far is the highest in the Australasian region (Australia, New Zealand) (Figure 1.1)
with a rate of 54 cases per 100,000, followed by North America with a rate of 21 cases per
100,000 population [2]. Current modelling to 2031 suggests that the incidence of melanoma is
set to increase among high-risk countries, including the US, UK, Australia and New Zealand,
especially in people older than 59 years of age [2]. However, a decline in new cases is expected
in age groups younger than 59 for people living in the Australasian region, with a stabilisation
predicted in the US and the UK [2]. The forecasted decrease in younger populations within
Australia may be attributed to the implementation of the “Slip, Slop, Slap” campaign, which
sought to implement sun protection behaviours. These include the use of shade and sunscreen
along with increased use of protective eyewear, hats and clothing [3].

Figure 1.1: Global melanoma incidence: Heat plot representing the worldwide incidence
rates of melanoma. Graphs were produced through the international agency for research on
cancer (http://gco.iarc.fr/today), utilising data from GLOBOCAN2018.
Cutaneous melanoma develops through the malignant transformation of skin cells known as
melanocytes. Melanocytes are the cells responsible for the development of skin pigmentation
in individuals through the production of melanin, which acts to protect against DNA damage
commonly caused by ultraviolet radiation [4]. Exposure to ultraviolet radiation causes an
accumulation of mutations within genes responsible for regulating cellular proliferation,
ultimately leading to the transformation from a melanocyte into melanoma [5].
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The initial stages attributed to the development of melanoma involve a series of transitions in
normal melanocytes (Figure 1.2). This transition involves changes from normal melanocytes
into dysplastic naevi [6]. These naevi have an increased proliferation rate and are generally
benign. Further dysplastic growth is characterised by the formation of atypical structures
containing varying amounts of pigmentation. Progression is marked by a radial growth phase
and expansion of the cells, before transitioning into a pattern of vertical invasion into the dermis
[6]. Further investigation into the developmental phase of melanoma details differences
dependent on the level of sun damage the skin has received. In skin that has been chronically
sun damaged, they are not often associated with a naevi transitioning into melanoma [7].

Figure 1.2: Development of melanoma: Initially, normal melanocytes acquire genetic
aberrations triggering uncontrolled growth and formation of the nevus. This nevus will begin
a radial growth phase and subsequent vertical growth phase marked by invasion into the dermis.
Adapted from H. Liu et al [8].

1.1 Staging of melanoma
The current staging of melanoma is described in the eighth edition of the American Joint
Committee on Cancer (AJCC) [9]. This staging is based on measurements of the primary
tumour (T), regional lymph nodes (N) and distant metastases (M) [9]. Primary tumour
ulceration status separates cases into those without (A) and with ulceration (B). Patients with
primary tumour ulceration appear to have lower survival rates than those without [10]. The
combination of thickness and ulceration is used to clinically stage patients as stage I or II. Stage
I is defined as having a tumour thickness of 0-1mm, or up to 2mm with ulceration. Stage II is
defined with a thickness of 1-4mm regardless of ulceration. Stage III requires the presence of
18

tumour cells within the skin or subcutaneous tissue that surrounds the primary tumour, a nearby
lymph node, or “in-transit” skin or subcutaneous deposits between the primary tumour and
draining lymph nodes (N). Stage IV is defined by the identification of a distant metastatic site
(M), regardless of lymph node involvement or primary tumour thickness. Computed
tomography (CT) and positron emission tomography (PET) are the primary imaging tools used
to assess the extent of metastases in late-stage melanoma [11]. The presence of brain metastases
is usually assessed by contrast-enhanced magnetic resonance imaging (MRI) [12].

1.2 Mutations in melanoma
Driving mutations in melanoma
Melanoma has one of the highest rates of somatic mutations in cancer, rivalled only by other
types of skin cancer [13, 14]. The initiation and progression of melanoma is marked by the
alteration in critical genes, including BRAF, NRAS, PTEN, TP53 and CDNK2A [15]. Tumour
suppressor CDKN2A encodes for two key proteins, p16INK4A and p14ARF, which restrain
cell division via the inhibition of cyclin-dependent kinases [15]. Phosphatase and tensin
homolog (PTEN) encodes for another tumour suppressor that is a negative regulator of the
PI3K pathway [15]. Genetic profiling and functional studies have demonstrated that aberrations
affecting these two tumour-suppressor genes cooperate with oncogenic mutations in BRAF or
NRAS, driving melanomagenesis [16, 17]. Integrative analysis has established a framework for
the genomic classification of cutaneous melanomas into four subtypes; BRAF, NRAS, NF1
mutant or triple wild-type [15, 16]. Tumours defined as triple wild-type are predicted to
harbour less tumour burden and uncommon driving mutations [16]. BRAF is mutated in
roughly 52% of melanomas, NRAS in 28% and NF1 in 14% [16]. All three genes are involved
in activating the mitogen-activated protein kinase (MAPK) pathway, a critical oncogenic
signalling pathway in the development and maintenance of malignant melanoma [16, 18].

Mutations in the MAPK pathway
The MAPK pathway consists of RAF, MEK and ERK kinases, which are crucial proteins that
relay extracellular signals into the nucleus, causing the activation of downstream genes
promoting cellular proliferation [19]. The deregulation of regulators critical to the MAPK
pathway, or mutations within, cause the uncontrolled activation of the pathway, resulting in
persistent cellular proliferation within the melanocyte, which leads to melanoma [19]. The most
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common activating mutations affecting the MAPK pathway are in the NRAS, BRAF, NF1 and
MEK1/2 genes (Figure 1.3).
NRAS is a GTPase (guanosine triphosphate) involved in transmitting signals within cells and
regulating important cellular processes, including cell proliferation and survival [20]. The main
mutation in NRAS that is relevant to melanoma is located at codon 61 [16]. This mutation leads
to a loss of the intrinsic GTPase activity, locking the protein in an activated state, which
continually stimulates RAF dimerization and activation of the downstream cascade [16].
NF1 is a tumour suppressor gene that encodes a RAS GTPase activating protein involved in
regulating RAS [21]. Negative regulation of the MAPK pathway is achieved by suppressing
RAS activity, thereby reducing RAS-GTP levels and promoting endogenous RAS GTPase
[22]. NF1 constrains RAS activity in a normal cell, therefore mutations in NF1 lead to an
elevation in RAS activity, resulting in unregulated cell growth and tumorigenesis [18, 22]. RAF
proteins are separated into 3 serine/threonine kinases, including ARAF, BRAF and CRAF with
each controlling one portion of the MAPK pathway [23]. RAF signalling is activated through
receptor tyrosine kinases (RTKs) and the activation of GTPase RAS [23]. Activated RAF
phosphorylates MEK, which subsequently phosphorylates ERK through its N-terminal domain
[24]. Mutant BRAF acts independently of NRAS, leading to uncontrolled activation of the
MAPK pathway and enhanced cellular proliferation [25, 26]. BRAF is the most commonly
mutated gene in melanoma, with the V600E mutation accounting for roughly 87% of BRAF
mutant cases [16]. Other mutant forms include the BRAF V600K and V600R mutations, which
account for 10% and 3% of cases respectively [16]. MEK1 can also carry activating mutations
in around 8% of melanomas and can be found associated with BRAF or NRAS activating
mutations [27].
Ultimately the activation of the MAPK pathway, through the acquisition of mutations, results
in uncontrolled proliferation and development of melanoma. This inherent reliance has resulted
in the development of effective therapies that target mutant proteins produced by these
mutations.
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Figure 1.3: MAPK pathway: Activating mutations in genes within the MAPK pathway results
in the override of apoptotic signalling and induction of constant cell proliferation. Proteins in
the MAPK pathway known to carry mutations are identified by an asterisk and occur primarily
in BRAF, NRAS and NF1, and to a lesser extent in MEK1/2.

1.3 MAPK targeted therapies
Historically, metastatic melanoma has been a challenging disease to treat. The use of the DNA
alkylating agent dacarbazine, used to be the standard of care for the treatment of melanoma
[28, 29]. However, its effectiveness in prolonging patient survival was very limited, with a
median progression free survival (PFS) of 2.7 months [28, 29]. A breakthrough early in the last
decade enabled the specific targeting of mutant BRAF and MEK as a new therapy for
metastatic melanoma. In parallel to the development of targeted therapies, further
breakthroughs were achieved with immune checkpoint inhibitors, which enable the immune
system to recognise and destroy malignant melanoma.

MAPK targeting therapy
The development of inhibitors specific for mutant BRAF was an exciting paradigm shift in
melanoma treatment [29, 30]. Vemurafenib and dabrafenib are selective BRAF inhibitors
(BRAFi) that preferentially block mutant BRAF kinase activity, preventing MAPK pathway
activation and ultimately halting melanoma growth [31]. Vemurafenib was the first agent
21

developed with high specificity for the V600E mutant BRAF to enter clinical trials. This
inhibitor has equal effectiveness with CRAF, but is less effective with other BRAF mutations
including V600K, V600R and V600D [32]. Dabrafenib is another BRAFi, which has cross
reactivity with V600E and V600K variants, but is less versatile against CRAF [32]. Further
advancement in this field has led to the development of encorafenib, a second generation
BRAFi. Encorafenib can provide greater MAPK inhibition without triggering the paradoxical
activation of the MAPK pathway, otherwise seen in both dabrafenib and vemurafenib [33]. The
advantage is seen in its significantly longer dissociation half-life of 30 hours, in comparison to
2 hours with dabrafenib and 30 minutes with vemurafenib in BRAF mutant cell lines [34].
At the time of introducing these inhibitors, chemotherapy was the standard of care of used to
evaluate these upcoming treatments [35]. The evaluation of vemurafenib versus dacarbazine
within the study BRIM-3 demonstrated a relative risk reduction of 63%, and a substantial
reduction

of

74%,

in

the

risk

of

death

and

disease

progression

[35].

Similar results were observed with the introduction of dabrafenib against dacarbazine [29].
Over an observed period of nine months, a median PFS was established of 5.1 months on
dabrafenib as opposed to 2.7 months on dacarbazine, with a hazard ratio of 0.3. This indicates
a substantial reduction of risk to patients [29]. The perceived benefit of these treatments
accelerated the uptake and approval of BRAFi in the treatment of melanoma.

Combination BRAF-MEK inhibitors
The advent of single agent BRAFi permanently altered the landscape of melanoma treatment.
However, this therapy was limited due to the development of treatment resistance. This
resistance can be mitigated to a degree through the addition of MEK inhibitors (MEKi)
trametininb, cobimetinib or binimetinib. Preliminary investigation of MEKis evaluated their
use of them in a single therapy setting [36]. Unfortunately, they were found to be less effective
then BRAF monotherapy [36]. However, the combination of both MEK and BRAFi was found
to be more effective in comparison to BRAF inhibition alone. Two landmark studies, COMBId and COMBI-v, evaluated the use of dabrafenib and trametinib versus either vemurafenib
alone or dabrafenib alone [37]. Over a period of twelve months, the combination of dabrafenib
and trametinib was found to be superior in providing improved PFS and a reduced hazard ratio
of 0.63[38].
Similar results were established through the use of vemurafenib plus cobimetinib versus
vemurafenib alone, achieving a reduced hazard ratio of 0.51 [39]. Combination therapies have
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provided significant benefits for the long-term overall survival, with approximately 30-40% of
patients still alive after 5 years on either combination treatment [37, 40].
Further expansion into the new BRAFi encorafenib, and the MEK inhibitor binimetinib, were
evaluated against vemurafenib alone or encorafenib alone over a period of 24 months [41].
This combination had a significant reduction in hazard ratio to 0.54 in comparison to
vemurafenib alone, and a ratio of 0.75 in comparison to encorafenib alone [41].
Based on the effectiveness of this combination therapy in late stage melanoma, this treatment
regime has been expanded for the treatment for loco-regional disease (stage III) [42]. The
COMBI-AD trial evaluates the efficacy of dabrafenib/trametinib vs placebo in stage III patients
[42]. Overall 52% of patients were still alive and relapse free five years after treatment, with a
hazard ratio of 0.51 [42]. This demonstrates the effectiveness of earlier intervention to prevent
disease spread.

1.4 Development of resistance to BRAF inhibitors
The development of drug resistance ultimately hampers the effectiveness of BRAFi therapy for
the management of melanoma. Despite significant early benefit, the median time to progression
indicating the development of resistance, has been approximately 12 months [43].
Resistance to MAPK inhibition is a multifaceted phenomenon and a complex scenario
involving genetic, epigenetic and metabolic changes within the tumour cells and the tumour
microenvironment. Here, the various mechanisms underlying treatment failure have been
categorised into those conferring intrinsic, adaptive, and acquired resistance (Figure 1.4).
Potential strategies to overcome these mechanisms of resistance have been highlighted.
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Figure 1.4: Mechanisms conferring intrinsic, adaptive and acquired resistance in BRAFmutant melanomas: Adapted from Tangella et al. [44].

Intrinsic resistance
Despite carrying a BRAF V600E mutation, around 1 in 5 melanoma patients treated with
BRAFis show disease progression on their first assessment during treatment. This suggests that
a substantial proportion of cells within these tumours harbour intrinsic resistance mechanisms
that render primary drug resistance [45].
The presence of certain genetic alterations can render the effectiveness of BRAFis inert. For
example, the loss or mutation PTEN is frequently identified in BRAF-mutant melanoma and is
a major regulator of the phosphatidylinositol-3-kinase (PI3K) pathway [16, 46]. Melanoma
patients who lack PTEN expression due to an alteration/mutation and treated with BRAFi had
a shorter median PFS and overall survival but similar overall response rates [46, 47]. Only 10%
of PTEN-null BRAF mutant melanomas exhibited intrinsic resistance to BRAFis, which
suggests that the contribution of PTEN to resistance may be contextual, but overall can reduce
treatment effectiveness [46, 48].
Genome-scale screening using RNAi and CRISPR-Cas9 have implicated NF1 loss in the
resistance to BRAF inhibitors [49, 50]. NF1 plays an important role in the suppression of RAS,
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constraining the MAPK pathway [49]. Importantly, endogenous NF1 alterations were found in
pre-treatment tumours of patients who were refractory to vemurafenib treatment demonstrating
the clinical significance of NF1-driven resistance [49]. Similarly, pre-existing MEK1P124
mutations have been attributed to shorter PFS in BRAF-mutant melanomas treated with
BRAFis [51]. Other alterations shown to be implicated in intrinsic resistance to BRAF
inhibition include the RAC1P29S mutation [48] and overexpression of cyclin D1. In addition,
low basal RHOB expression in melanoma cells lines correlated with BRAFi sensitivity, while
depletion of RHOB restored sensitivity to MAPK inhibition [52]. Analysis of biopsies from
patients treated with vemurafenib, indicated significantly shorter PFS in patients whose tumour
samples displayed a positive RHOB staining before treatment compared to those with negative
RHOB staining. It is thought that activation of the c-Jun/RHOB axis affects the response to
BRAFis through the activation of the AKT pathway [52].
Adaptive response and drug tolerance
Despite the initial tumour reduction observed in most melanoma patients treated with BRAFis,
complete tumour regression occurs rarely. This is due to the emergence of BRAFi induced
compensatory mechanisms, referred here as adaptive responses, that enhance the pro-survival
and pro-proliferative capacity of a proportion of the original tumour population. These adaptive
responses are temporary responses that are reversible, and not transferrable to the progeny cells.
Some of these mechanisms involve the loss of negative feedback loops. BRAFi sensitive
BRAFV600E mutant cells exhibit low expression of RAS-GTP before treatment, due to ERKdependent feedback suppression of the RTK signalling [53]. Active ERK can directly regulate
signalling intermediates, such as EGFR and SOS, or indirectly activate the expression of
negative feedback regulators such as SPROUTY (SPRY) and DUSP proteins [53] (Figure 1.5).
Inhibition of the MAPK pathway by BRAFis relieves this feedback, resulting in the
reactivation of multiple pathways and attenuation of the antitumor effects of the targeted
inhibitors [54]. This adaptation occurs in hours, thus diminishing the effectiveness of the
therapy.
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Figure 1.5: Loss of negative feedback regulation of ERK: ERK activation controls MAPK
pathway activation through negative feedback loops through the upregulation of SPRY and
DUSP. SPRY inhibits SOS phosphorylation, dampening MAKP activation. BOP1 and STAG
are both regulators of DUSP, which inhibits ERK phosphorylation and maintain control of the
MAPK pathway. Loss of function mutations in STAG2, and downregulation of BOP1 results
in reduced control of phosphorylated ERK, allowing cell survival and resistance to BRAFis.
Alternatively, dynamic cell-state transitions result in cell subsets with diverse sensitivity to
BRAF inhibition. The identification of distinctively high and low microphthalmia-associated
transcription factor (MITF) levels within a melanoma tumour population [55] marked the
conceptualisation of the MITF-rheostat model [56]. MITF is a melanocytic-lineage
transcriptional factor crucial for early melanogenesis and differentiation of melanocytes and is
a master regulator of several biological processes in melanoma cells such as invasion, survival,
cell cycle regulation and autophagy [57-59]. The MITFhigh population expressed genes
associated with the proliferation of cells and retain sensitivity to BRAFis [55, 60, 61]. On the
other hand, the MITFlow population expressed genes associated with invasiveness and
conferred resistance to targeted therapy [56, 60, 61]. Numerous studies have confirmed that
intrinsic resistance is conferred by the AXLhigh and MITFlow phenotype in response to MAPK
inhibition in melanoma cells [60-63].
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In notable contrast with the above observations, the upregulation of MITF has also been
identified as a driver of a drug tolerance state [64]. High MITF expression and of MITF target
genes during BRAFi treatment were linked to resistance [65]. Upregulation of MITF expression
is an early driver of the non-mutational drug tolerant state in melanoma cells and is linked to
intrinsic resistance [48, 61, 64, 66-70]. Thus, both MITFhigh and MITFlow phenotypes have been
linked to innate resistance in melanoma cells.

Acquired Resistance
Around 50% of patients treated with BRAFis alone or in combination with MEKis experience
an initial significant shrinking of the tumour followed by tumour outgrowth, due to the
emergence of acquired resistance. This resistance often occurs due to the acquisition of a
mutation that either reactivate the MAPK pathway or circumvents the MAPK pathway
altogether through the utilisation of alternative pathways to support cellular growth.
MAPK reactivation-based resistance mechanisms
RTKs act as upstream activators of MAPK signalling. Nazarian et al. first demonstrated that
increased expression of PDGFRβ conferred resistance to BRAFis [71], which was further
demonstrated by others using different cell lines [72, 73]. In contrast, another study showed
increased expression of EGFR, KIT and MET with decreased expression of PDGFRβ in
resistant M249 cells [74]. Supra-physiologic levels of c-MET transcripts have been found
BRAFi resistant melanomas [75]. A study by Shaffer et al. suggested that multiple RTKs, such
as AXL, EGFR, PDGFRβ and JUN are expressed in a small subpopulation of melanoma cells
prior to treatment by non-heritable, transient expression [63]. BRAFi treatment selects for
increased proportion of cells expressing these RTKs, which mediate resistance through the
activation of the MAPK pathway or alternative PI3K/AKT pathway.
NRAS serves as an activating mutation within melanoma encompassing around 28% of
melanomas, with Q61R being the most common [16]. NRAS mutants preside within both
combinational and monotherapy cohorts [71, 76]. NRAS mutations are a resistance mechanism
that occurs in 5-18% [77-79]. Resistant cells with secondary NRASQ61K mutation require CRAF
expression and SHOC2 scaffold protein to re-activate MAPK [80]. BRAF inhibition
specifically, not drug binding, drives wild-type BRAF binding to CRAF and activation of MEK
[81]. Despite the theoretical and preclinical support for CRAF overexpression as a mediator of
BRAFi resistance, this concept has not been validated in a clinical setting [82].
MEK1 mutations are rare in melanoma and are often associated with either BRAF or NRAS
mutations [16]. MEK1 mutations within either exon 3 or 6 were found to confer resistance to
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BRAF inhibition [83]. Further studies support that MEK1 mutations in BRAFV600E melanomas
are linked to both intrinsic and acquired resistance to BRAFis [51, 84]. Various meta-analyses
have described an overall incidence of 7-8% for MEK1/2 mutations in BRAFi monotherapy
and BRAFi plus MEKi resistant melanomas [76, 77]. In contrast, Shi et al. showed that preexisting exon 3 mutations, MEKP124S and MEK111S, do not confer resistance to vemurafenib
[85]. It has been postulated MEK1 exon 3 mutations are not constitutively activating but render
MEK1 more readily activated. Further studies are required to disentangle the role of MEK
mutations in pathogenesis and treatment resistance of melanoma.
The overproduction of BRAFV600E due to the genetic amplification of the mutant gene has been
established as a common mechanism of resistance to both BRAFi or BRAFi plus MEKi [76,
86]. The prevalence of this amplification was confirmed in larger studies of clinical specimens
[76-79]. BRAFV600E amplification drives resistance through the excess generation of activated
MEK, which in turn activates downstream constitutes of the MAPK pathway. BRAF
amplification and alternative splicing were observed most frequently followed by NRAS
mutations and MEK1/2 mutations [77].
Resistance to BRAFis are also conferred through the production of aberrantly spliced
BRAFV600E isoforms that lack the RAS binding domain (RBD) encoded by exons 3-5 [87].
These splicing variants lack the RBD and can dimerize in the presence of low levels of RAS
and confer drug resistance [87]. Four BRAF splicing variants have been described and are
called p61, p55, p48 and p41 based on their predicted molecular weight [87]. Alternative BRAF
spliced isoforms have been identified in patients progressing on BRAFi alone and in
combination with MEKis and as in preclinical models [87-90]. In fact, expression of aberrantly
spliced BRAF V600E isoforms mediates resistance in 13–30% of melanoma patients [77-79].
Although BRAF splicing variants are capable of conferring resistance to BRAFi, cell line
studies have shown that melanoma cells carrying splicing variant remained susceptible to MEK
inhibition [76]. Moreover, the enhanced association between BRAF splicing variants and their
substrate, MEK, is required for resistance to BRAFis [91].
The Ser/Thr MAP kinase MAP3K8 (or COT) has the potential to directly phosphorylate MEK
to trigger downstream cascades. Johannessen et al. reported that COT expression was
associated with acquired resistance to BRAFi in melanoma cell lines and tissue obtained from
relapsing patients following treatment with MEKis or RAF inhibitors [92]. Over activation of
MEK within the cell line A375 was established to occur through COT signalling, also
generating resistance to selumetinib and CI-1040 [92].
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Loss-of-function mutations in STAG2 and decreased expression of STAG2 and STAG3
proteins have been identified in BRAFi-resistant cell lines and in several tumour samples from
patients with acquired resistance [93]. Furthermore, STAG3 mutations were found in 3 of 14
pre-treatment samples from patients who developed resistance vemurafenib within 12 weeks
of treatment and the post-relapse sample of another 6 cases [93], suggesting that STAG2
mutations can mediate intrinsic and

acquired BRAFi resistance (Figure 1.5). STAG2

knockdown lead to decreased dual-specificity phosphatase 6 (DUSP6). DUSP6 acts as a
negative regulator of ERK activation [94]. Thus, STAG2/3 alterations result in ERK activation,
by limiting dephosphorylation [94].
The ribosome biogenesis protein block of proliferation 1 (BOP1) acts as a regulator of DUSP4
and DUSP6 [94, 95]. Unlike STAG knockdown, which resulted in a reduction in DUSP6 but
not DUSP4, loss of BOP1 generated a reduction in both, leading to an increase in MAPK
signalling (Figure 1.5) [93, 95]. A small scale investigation into patient samples both pre and
post BRAFi alone or in combination with MEKi revealed a reduced protein expression of
BOP1 within 7 of the 11 cases that relapsed [95]. The results of this preliminary study highlight
another escape mechanism that can be utilised by melanomas [95].
MAPK independent based resistance mechanisms
Another established pathway is PI3K/AKT [96]. The induction of the PI3K-AKT by insulin
could protect BRAFV600E cells from vemurafenib [97]. Cross-talk between the PI3K and MAPK
pathways have been established, with BRAFi resistant cell lines utilising AKT to trigger ERK
within MAPK for cell survival, circumventing both BRAFis and MEKis [98]. AKT1 mutant
based resistance to BRAFis has been identified previously in progressive patient samples to
monotherapy [78]. Recent work demonstrated that PI3K activity is capable of promoting
survival but not proliferation of cell lines when challenged with BRAFis plus MEKis [99].
Continuous BRAFi in BRAF-mutant cell lines results in elevated WNT5A transcripts.
Furthermore, 7 out of 11 tumours from patients who progressed in BRAFis presented increased
WNT5A expression compared to pre-treatment samples [100]. In vitro studies demonstrated
that a loss of WNT5A reduced the viability of the cells in the presence of BRAFis [100].
WNT5A overcomes BRAF inhibition through the increased phosphorylation of AKT and
activation of RYK and FZD7 receptors supporting non-canonical WNT signalling [100].
Overall, acquired resistance to BRAF inhibition depends on oncogenic signalling through
reactivation of MAPK or activation of an alternative pathway such as the PI3K/AKT pathway.
Resistance can be acquired by upregulation of receptor tyrosine kinases signalling, by directly
affecting genes in these pathways, or by enhancing downstream signalling. However, the
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mechanisms underlying acquired drug resistance are hugely diverse, with evidence of high
inter- and intra-tumour heterogeneity [101].

1.5 The Dawn of Immunotherapy
Harnessing the immune system to combat cancer has evolved during the last decade from a
promising therapy option to a robust clinical reality. Initial success using adoptive T-cell
therapy indicated the potential of this therapeutic modality [102]. However, the introduction of
immune checkpoint inhibitors, including anti-CTLA-4 which was succeeded by anti-PD-1
antibodies, has revolutionised the treatment of metastatic melanoma. These provide a viable
treatment option for patients with melanoma, irrespective of BRAF mutation status. Immune
checkpoint inhibitors are now approved as a first-line therapy on the pharmaceutical benefits
scheme (PBS) in Australia, regardless of patient BRAF status [103].

Anti-CTLA-4 therapy
T cells are activated when the T-cell receptor complex binds to an antigen that is presented via
the major histocompatibility complex (MHC) [104]. In addition, the co-stimulatory interaction
of CD28 on the T cell with B7 (CD80/86) on the antigen-presenting cell, is critical for T-cell
proliferation [104]. CTLA-4 is a homologue of CD28 that has a higher affinity for binding to
CD80/86 [104]. This binding of CTLA-4 prevents the activating signal to the T cell and instead
generates an inhibitory signal [104].
Antibodies such as ipilimumab and tremelimumab, target CTLA-4 to disrupt the interaction of
CD80/86 with CD28. This subsequently prevents inhibition of cytokine production and T cell
proliferation. [31, 104, 105]. A phase 3 clinical trial demonstrated that survival rates were
significantly higher in patients receiving ipilimumab plus dacarbazine, compared to those
receiving dacarbazine at 1 year (47.3% vs. 36.3%), 2 years (28.5% vs. 17.9%), and 3 years
(20.8% vs. 12.2%) post treatment [106]. The introduction of ipilimumab plus dacarbazine had
a dramatic reduction in the hazard ratio of 0.33 [106]. A separate, long term study established
an improved efficacy of what was observed previously, but with an overall survival of only
26% [107]. A disappointing outcome for this new therapy [107].

Anti-PD-1 therapy
Programmed cell death protein 1 (PD-1) is a receptor expressed by activated T cells [108, 109].
PD-1 is a co-inhibitory receptor capable of downregulating T-cell activation through the
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ligation of PD-L1 or L2 [110]. This pathway is often hijacked by tumour cells to evade immune
detection and destruction through the expression of PD-L1 [110].
Nivolumab and pembrolizumab are two monoclonal antibodies designed to bind to the PD-1
receptor on T cells, preventing the binding of either PD-L1 or L2. In the absence of this
inhibitory signal, T-cell activation can occur against presented antigens [108-110]. The
introduction of this type of therapy has had profound benefits for patient survival, with patients
receiving nivolumab monotherapy having an overall survival rate of 44% at five years [107].
Pembrolizumab has shown similar improvements with an overall survival rate of 38.7% at five
years, and a reduced hazard ratio of 0.73 [111].
Overall, treatment with PD-1 inhibitors has greatly improved the survival of late-stage
melanoma patients, with a large proportion of patients likely to maintain long lasting response
to this treatment, even after therapy cessation [112].

Anti-CTLA-4 and anti-PD-1 combination therapy
Combinations of PD-1 and CTLA-4 inhibitors have also been investigated as an option to
increase therapeutic efficacy. A phase 3 clinical trial evaluated the combination of nivolumab
and ipilimumab in comparison to their respective monotherapies in untreated melanoma
patients [113]. The results confirm an improvement in PFS and response rates in both
nivolumab and a combination of nivolumab/ipilimumab, in comparison to ipilimumab alone
[113]. In the two year follow up of patients on a combination of ipilimumab/nivolumab, overall
survival was found to be 63.8% at two years for ipilimumab plus nivolumab, while ipilimumab
monotherapy had an overall survival of 53.6%, with a hazard ratio of 0.36 [114]. Which
indicates that the combination is highly beneficial for extending PFS [114]. Subsequent followup of this cohort after five years demonstrated improved overall survival rates of 52% for the
combination and 44% for the nivolumab alone, as opposed to only 26% of patients on the
ipilimumab monotherapy [107]. However, the benefit that combination immunotherapy
provides comes with an additional increase in the percentage of grade 3 or 4 adverse effects,
compared to nivolumab alone (59% vs 23%) [107]. These adverse events are debilitating for
patients and occasionally life-threatening, along with imposing additional burdens on the health
care system [107].

31

Adjuvant immunotherapy or targeted therapy
With the approval of effective therapies for the treatment of unresectable or metastatic
melanoma, recent clinical trials have focused on the adjuvant treatment of patients with stage
II and III melanoma, to reduce the risk of recurrence.
Compared to placebo, ipilimumab based adjuvant therapy resulted in an improved overall
survival at five years in patients with resected stage IIIB/C melanoma (65.4% vs 54.4%), with
a hazard ratio of 0.76 [115]. The treatment of completely resected stage III melanoma with PD1 inhibitors has also resulted in reduced risk of recurrence for both nivolumab and
pembrolizumab [116, 117]. Treatment with nivolumab of stage IIIB/C disease showed patients
had higher rates of recurrence-free survival (72.3%), while those on ipilimumab had lower rates
(61.6%), with a hazard ratio of 0.65 [117]. This Indicates that nivolumab was a more effective
therapy [117]. In comparison to placebo, treatment with pembrolizumab significantly improved
the percentage of patients who were recurrence-free at 18 months (71.4% vs 53.2%), with a
hazard ratio of 0.57 [116].
The ability to intervene therapeutically in stage III patients has proven effective in delaying
disease progression. Both pembrolizumab and nivolumab are under evaluation in stage IIB/C
patients who are deemed as high risk (KEYNOTE-716 and CheckMate 76K), to determine if
earlier stage intervention may curb development of recurrent or advanced disease [118].

1.6 Circulating Biomarkers
Broadly, circulating biomarkers include any tumour-derived material that circulates within the
blood stream that could provide information pertinent to the cancer. This information can alter
decisions in the management of cancer [119, 120]. These materials include tumour derived
DNA, RNA, proteins, extracellular vesicles and circulating tumour cells (CTCs) [119, 120].
Components of tumours shed into circulation can be detected and used for disease monitoring,
to predict response to therapies and identify drug resistance [121-124]. Historically, the most
used blood-based marker approved for melanoma patient monitoring was lactate
dehydrogenase (LDH). Overall, patients who have elevated levels of LDH have worse survival
rates when compared to patients with LDH levels within the normal reference range (140280U/L) [125]. Although LDH levels appear to be indicative of survival, elevated levels have
been reported in as few as 21% of patients [126]. Furthermore, LDH has been found to not be
indicative of metabolic tumour burden in patients [126]. Other protein markers, including S100
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and Melanoma Inhibitory Activity (MIA), have been evaluated but are yet to be approved for
clinical use [126-130].
Liquid biopsies, which encompass the analysis of CTCs, circulating tumour DNA (ctDNA),
circulating miRNA and tumour-derived EVs, have become increasingly more feasible over the
last decade [121, 131-134]. In melanoma, several studies have shown the significance of CTCs
as indicators of patient survival and predictors of response to treatment [135-138]. A CTC score
of >100 was an indicator of poor prognosis in melanoma, while the absence of CTCs was a
strong predictor of a longer PFS [137]. In addition to the number of CTCs, the characterisation
of markers present on CTCs has been explored. The presence PD-L1+ CTCs is indicative of a
longer PFS, with 81% of patients not experiencing disease progression after 1 year [138].
Although CTCs have the potential to provide important clinical information to monitor
treatment response, the utility of this marker is constrained by the ability to reliably isolate
these cells from patient samples.

Circulating tumour DNA (ctDNA)
Plasma ctDNA are small fragments (~160bp) of tumour DNA shed by cancer cells within the
tumour, or while in circulation [139]. These DNA fragments are detectable in cancer patients
and have potential use for diagnosis, prognosis and monitoring of cancer [121, 140]. In
melanoma, patients who have undetectable plasma ctDNA levels prior to commencing
treatment have longer survival time, suggesting a predictive role for ctDNA in this setting [141144].
In patients with stage II and III melanoma, detectable ctDNA levels have been shown to
correlate with overall survival outcomes and are therefore indicative of increased risk of local
disease progression and the development of distant metastases [145, 146]. In light of these
results, the presence of ctDNA is being tested in stage II and III melanoma as an indicator of
patients that are in more critical need of adjuvant therapy [145-147].
In patients with metastatic melanoma, the prognostic value of ctDNA has been shown by
multiple studies in both late stage and earlier stage patients treated with MAPK inhibitors and
immune-directed therapies [121, 131, 144, 146, 148-150]. Detectable plasma ctDNA after
treatment initiation has been shown to be indicative of both reduced progression free and
overall survival [131, 140]. Moreover, prognosis is often poor for those who maintain
detectable levels of ctDNA in comparison to the baseline while on therapy [131, 140, 141].
The monitoring of ctDNA within immunotherapy has the potential to better inform on patient
response, allowing for earlier interventions to promote better patient outcomes [140] .
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Furthermore, ctDNA provides an alternative sample for tumour genotyping [149], which can
be assessed regularly. Targeted therapy has the inevitable outcome of treatment failure, which
has led to the evaluation of ctDNA as an early predictor of failure, prior to conventional
monitoring of disease [121, 151]. The assessment of ctDNA has revealed the emergence of
resistance mediating mutations such as NRAS, MEK and PTEN in patients failing MAPK
targeted therapies [121, 150, 151].
Although ctDNA has shown promise as an indicator of patient outcomes and tumour genetics,
there are several limitations with the implementation of this biomarker within the clinical
space. One of the most reported concerns regarding the characterisation of ctDNA, are the preanalytical factors. These factors include, the type of blood tube used, the time from collection
to processing and the temperature at which the contents are transported [152-156]. Collectively,
these variables have been found to drastically influence the levels of cell-free DNA present.
Longer periods between collection and processing will generally lead to increased levels of
genomic DNA, thought to be from white blood cells that have lysed within tubes that do not
have a fixative step. In addition, the presence of ctDNA itself correlates to tumour burden,
activity and the physical location of the tumour [157].

1.7 Extracellular vesicles
Extracellular vesicles (EVs) were first described by Pan and Johnstone in the early 1980’s, and
were initially considered to be part of a disposal mechanism to discard unwanted materials
from cells [158]. With an explosion of research in the field, it is now known that the release of
EVs is an important mediator of intercellular communication, that is involved in the normal
physiological process as well as pathological processes [159-162]. EVs are divided into three
classes; exosomes, microvesicles and apoptotic bodies (Table 1.1) [163].
Exosomes are a subclass of EVs that range from 30-120 nm in diameter [164] (Table 1.1).
Multiple studies have identified that exosomes contain proteins, cell surface molecules
including HLA’s, cytokines, growth factors, mRNA, miRNAs, and double stranded DNA
[161, 165-169].
Microvesicles are another subclass of EVs and have a larger range of 50-1000 nm in diameter
[164]. Less favoured than exosomes, microvesicles have still been established as mediators of
communication, resistance mediators and carriers of RNA [170-173].
Apoptotic bodies are the third subclass of EVs, and are the largest of the subgroups typically
starting at 50-2000 nm onwards [164]. Apoptotic bodies and apoptotic vesicles are some of the
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least studied subgroups of particles, therefore the impact of both apoptotic bodies and EVs
derived from apoptotic cells have become a new realm of interest [174, 175].
Given the overlap in size and characteristics of these different type of EVs, controversies have
arisen on the appropriate nomenclature to use when referring to these vesicles and reporting on
their specific functions. In addition, EVs will contain differing cargoes dependent on the cell
origin, complicating validation methodologies [176]. Therefore, guidelines regarding the
isolation and characterisation of EVs have been outlined by a consortium of leading researchers
within this field and recognised as the ‘Minimal information for studies of extracellular vesicles
2018 (MISEV2018)’ [177] [178]. These guidelines detail the minimal experimental
requirements for the validation of EV isolation and characterisation. In addition, these
guidelines underscore that at this current stage, there are no discernible markers to differentiate
exosomes from microvesicles. However, apoptotic bodies, can be identified through the
assessment of inter-cell components, including calnexin (endoplasmic reticulum), cytochrome
C (mitochondria) and nuclear histones [178].

Table 1.1 Extracellular vesicles sizes, biogenesis and key components
Extracellular
Size
Biogenesis
Key components
vesicle
Exosomes
30-120nm
Internal budding with Tetraspanins [166]
MVB fusion of the Transferrins [158]
plasma membrane to
secrete [179]
Microvesicles
50-1000nm Direct outward budding B1 integrin and
of the plasma membrane vesicle-associated
[179]
membrane protein 3 [179]
Apoptotic bodies 50-2000nm Formed through plasma Contains
cytosol
with
membrane blebbing and tightly packed organelles
cell fragment separation including
mitochondria
during a process of along with or without
“budding” [180]
nuclear fragments [180]
During endosome maturation, multi-vesicular bodies (MVBs) are formed by the inward
budding of the endosomal membrane (Figure 1.6) [181]. During this process, portions of the
cytosolic contents and transmembrane and peripheral proteins are engulfed into the
invaginating membrane to form intraluminal vesicles (ILVs) [181, 182]. ILV formation is the
first step of exosome biogenesis, and only occurs when the endosomal sorting complexes
required for transport (ESCRTs) are recruited to the site of ILV formation and the endosome
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membrane becomes highly enriched with tetraspanins [166, 183]. In addition to the ESCRT
formation pathway, an independent pathway has been identified involving areas rich in
ceramide, which are the trigger of ILV formation [184]. Further efforts to study the effects of
EVs have led to the development of inhibitors that prevent formation, including manumycin A
and GW4869 (Figure 1.6) [185].
The fate of ILVs after formation varies. Typically they fuse with the lysosome and their
contents are degraded [186]. Alternatively, they may fuse with the plasma membrane of the
cell and release their vesicles (exosomes) in an exocytotic fashion into the extracellular
environment [186].
Microvesicle release is triggered from the direct outward budding of the plasma membrane,
with release into the extracellular space [186, 187]. Alterations within the plasma membrane
at the site alter membrane rigidity, aiding in production. Unfortunately, the process by which
this class of EV is formed is still poorly understood [186, 187].
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Figure 1.6: Biogenesis and druggable targets of EV release: EVs are formed within the
endosomal network. Early endosomes will fuse with endocytic vesicles, organising content into
recycling endosomes and multi-vesicular bodies (MVB). The formation of these MVBs is
either Endosomal Sorting Complex Required for transport (ESCRT) dependant or independent.
Potential drug targets are manumycin A or GW4869 for the respective pathways. Both
pathways ultimately end with the release of exosomes. Adapted from Catalano et al. [185].

1.8 EVs in melanoma
Melanoma EVs involved in metastasis
One of the most widely investigated roles of melanoma derived EVs are their potential to
enhance metastasis. Melanoma EVs have the potential to mediate paracrine activities that foster
communication within the local tumour microenvironment and distantly through the
upregulation of angiogenic processes. These are concepts that have been reported previously
in other cancer types [188, 189].
Melanoma EVs have a unique ability to promote tubule branching and stimulate endothelial
angiogenic responses [190]. Subsequent works developed the idea that melanoma derived EVs
have the potential to prepare a pre-metastatic niche for invasion [191]. Through the use of in
vivo models it was established that, EVs tended to home towards sentinel lymph nodes
conducive to the recruitment and growth of melanoma cells [191]. RT-PCR of sentinel lymph
nodes revealed a significant increase in genes relating to cell recruitment, extracellular matrix
and vascular growth factors [191]. Melanoma EVs were also capable of preparing this niche in
the absence of a melanoma tumour [191]. While this work may not satisfy the current
requirements for confirming the true isolation of EVs, the data supports the idea of melanoma
EVs as primers for metastasis.
A subsequent study established a novel mechanism of metastatic spread through the education
of bone marrow progenitors via EVs from melanoma cells [161]. For this, EVs were isolated
from melanoma cell lines (B16, SK-Mel-28) by standard ultracentrifugation and validated
through size profiling, electron microscopy and western blotting for HSC70 and TSG-101.
However, a negative marker was not tested. Metastatic spread within in vivo models was
facilitated by the reprogramming of bone marrow progenitor cells, which was driven through
the uptake of EVs containing the receptor tyrosine kinase MET [161].
Subsequent works sought to identify differences in melanoma derived EVs from cell lines
thought to be either tumorigenic (SK-Mel-28 and DAJU) or metastatic (A375M and 1205Lu),
via a mass spectrometry approach [192]. Nanoparticle tracking analyses demonstrated the
expected size profile of EVs, while western blotting confirmed the presence of Flotillin-1,
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TSG-101 and CD81. However, negative markers were not assessed. EV proteins from all cell
lines were enriched with proteins, intracellular signalling cascades and intracellular transport
[192]. Specifically, cell motility was enriched only in metastatic lines and SK-Mel-28, while
proteins involved in angiogenesis and immune response were specifically enriched in EVs from
the metastatic lines [192]. This suggests that EVs derived from metastatic lines may play a role
in conditioning spaces for the formation of a pre-metastatic niche based on the cargoes that
they carry [192]
RAB27 has been established to be involved in the exocytosis of Multi-Vesicular Endosomes
(MVEs)

[193]. The silencing of RAB27A significantly reduced exosome production,

preventing bone marrow education, melanoma tumour growth in vivo along with the metastatic
ability of the tumours [161]. EVs were isolated by standard ultracentrifugation and were
validated through the detection of EV associated proteins CD9, TSG-101 and CD63. However,
a negative marker was not tested. The expression of RAB27 has been found to be increased in
melanoma cell lines and promotes the invasive capabilities of melanoma [194]. Similarly, the
silencing of RAB27A reduced the invasive capabilities of the melanoma cell lines WM164 and
WM983C [194]. However, this could be reversed through the addition of a conditioned
medium (free of FBS EVs) from the control cells, which suggest that EVs from the control
cells could re-instate invasiveness [194]. RAB27A has been found to be activated by
heterogeneous nuclear ribonucleoprotein H1 which is downstream of the MAPK pathway
[195]. Melanoma primarily develops from the constitutive activation of MAPK, which may
result in increased production of invasive EVs [16]. The investigation of RAB27A mRNA, in
a small group of ~70 stage III patients, demonstrated significantly improved survival rates in
patients with low expression of this marker [194].
Prominin-1 (CD133) is a pro-metastatic marker and a potential therapeutic target in melanoma
[196]. This protein was originally identified as a surface marker in neural and hematopoietic
stem cells [197, 198], and has been identified in both immortalised melanoma cell lines and
patient samples [199-201]. Recently it has been attributed to chemo-resistance within
melanoma cell lines [202]. This resistance was specifically through the activation of PI3K/AKT
pathway [202]. Furthermore, the ability of prominin to mediate chemoresistance has been
shown in colon-cancer [203].
Building on its potential, a bead-based isolation method was used to isolate prominin-1+ EVs
from the lymph node derived FEMX-1 melanoma cell line [204]. In this study, EVs were
validated using nanoparticle tracking analysis and western blotting for the EV associated
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protein Alix. However, no negative marker was used. EVs derived from FEMX-1 confirmed
the presence of prominin-1 [204].

Melanoma EVs in monitoring Targeted Therapy
The potential of melanoma derived EVs to predict response to therapy has been explored
previously [205]. Of the 372 miRNA’s explored, only two (miR-497-5p and let-7g-5p)
displayed potential as biomarkers of response. Shorter PFS was associated with the
downregulation of miR-497-5p in the EVs isolated from the plasma of melanoma patients on
targeted therapy. However, an receiver operating characteristic (ROC)-area under the curve
(AUC) of 0.68 suggests that this was not a strong indicator of response [205]. Patients who
exhibited no change in the expression of let-7g-5p during treatment exhibited better disease
control, this marker was highly correlated with response to treatment with a ROC-AUC of 0.95
[205].
Notably, in the aforementioned study EVs were isolated from plasma using a precipitationbased isolation kit (miRCURY) [205]. This method of EV isolation provides a high recovery
or yield of material, but is limited by specificity [205]. Subsequent RNA isolation was
performed using miRNeasy. Of concern, EV validation was unconvincing as western blotting
for CD63 yielded equivocal results and electron microscopy images were poorly resolved. As
the study used a precipitation-based method for EV isolation, the resulting preparation will
likely be a complex mixture of EVs and other contaminants that may confound the results.
Despite these limitations, this work contributes to the potential of EVs as a biomarker in the
melanoma space.

Melanoma EVs as conveyors of resistance
Vella et al. carried out an early preliminary investigation on the ability of EVs to transfer
BRAFi resistance in melanoma [206]. The authors utilised the melanoma cell line LM-MEL64R3, which is resistant to BRAFi through the overexpression of the RTK PDGFRβ [206, 207].
EVs were enriched using standard ultracentrifugation and validated by electron microscopy
and western blotting (positive for Alix, Syntenin and negative for Calnexin). LM-MEL-64R3
derived EVs carried the PDGFRβ protein. However, when added to the sensitive parental cells
(LM-MEL64), the EVs from the resistant cells provided no benefit to rescuing p-ERK from
inhibition [206]. In contrast, p-AKT was rescued when 100 and 200 µg/ml of EVs from
resistant cells were added [206]. As PDGFRβ is an RTK receptor capable of activating both
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MAPK and PI3K/AKT pathways [208], EV transfer contributed to BRAFi resistance through
a MAPK independent based mechanism [206].

Melanoma EVs in immune involvement
EVs derived from the plasma of melanoma patients has been shown to have the potential to
suppress immune cell functions [209]. The isolation of patient melanoma derived EVs was
achieved using a bead-based method targeting the Melanoma-associated Chondroitin Sulphate
Proteoglycan (MCSP) [210]. Incubation with patient plasma EVs with activated CD8+ T cells
revealed the ability of these melanoma EVs to downregulate CD69, an activation marker in T
cells [209]. Patient-derived EVs were capable of reducing the proliferation of CD8+ T cells, in
addition to downregulating NKG2D on NK cells [209]. This has been previously reported for
prostate cancer-derived EVs, with the suppression of NKG2D being a mechanism of immune
evasion [211]. Further immunological works have involved the derivation of EVs from mouse
melanoma lines. Specifically, EVs from the mouse melanoma cell line Ret were taken up by
immature myeloid cells and induced PD-L1 [212]. EV-treated immature myeloid cells became
immunosuppressed based on the dose-dependent inhibition of T-cell proliferation, an effect
that was reversible through the introduction of a PD-L1 antibody. Expansion into human
melanoma cell lines demonstrated the same effect on myeloid cells, with the upregulation of
PD-L1 on these cells [212]. This demonstrates the ability of melanoma EVs to interact with
both immature and mature myeloid cells to upregulate PD-L1, which in turn hampers T cell
activity. This also underscores the ability of melanoma derived EVs to act upon and dampen
both innate and adaptive immune responses.

Melanoma EVs for monitoring response to immunotherapy
Considering the importance of immunotherapy in the management of melanoma, the
expression of both tumour derived and serum PD-L1 have been measured to predict response
to immunotherapy [213, 214]. However, the validity of the marker remains controversial [213,
214]. The role of PD-L1+ EVs as an indicator of response to immunotherapy in melanoma has
been investigated recently [215]. A comparison of soluble serum PD-L1 or PD-L1+
microvesicles and EVs was completed using a cohort of 44 patients with either stage III or IV
melanoma, undergoing treatment with pembrolizumab [215]. EVs from plasma isolated by
ultracentrifugation were validated using electron microscopy, nanoparticle tracking analysis
and western blotting (CD63, Alix and TSG101). Low levels of PD-L1+ EVs prior to treatment
were predictive of response, in comparison to either serum PD-L1 or PD-L1+ microvesicles,
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demonstrating the importance of the specific isolation of EVs [215]. A subsequent study
investigated a similar concept in an additional 46 melanoma patients, but showed that PD-L1+
EV levels were not significantly different at baseline, in comparison to subsequent samples
taken during treatment in patients who responded [216]. However, patients who failed therapy
had a significant increase in the expression of PD-L1+ EVs (p<0.0002). These outcomes
suggest that although circulating PD-L1 remains controversial as a marker of response for
patients, PD-L1+ EVs may offer a more objective marker of response.

1.9 Theoretical Framework, Hypothesis and Aims
Despite drastic improvements in the clinical management and treatment of melanoma through
the development of targeted and immune directed therapies, these treatments still fail many
patients. In the case of targeted therapy, patients invariably fail treatment through the
development of resistance, ultimately compromising treatment benefit and shortening survival
[77, 78]. The characterisation of resistant tumours has revealed several mechanisms involved
in treatment failure [77, 78, 101]. Tumours that are resistant and progressing contain
populations of both sensitive and resistant cells, which prompted the theory that resistant cells
can protect sensitive cells through the secretion of soluble factors [121, 150, 151]. A potential
mechanism responsible for transferring drug resistance is the exchange of EV cargoes between
cells, as shown in previous studies in breast, colorectal, hepatocellular carcinoma and
melanoma EVs [206, 217-220]. However, the presence of canonical resistance mediators
within EVs, and the capacity of EVs to transfer resistance to sensitive cells has not been widely
investigated in melanoma.
Anti-PD-1 immunotherapies have drastically altered the outcomes of melanoma patients [107].
Unfortunately, the reality is that not all patients respond to this line of treatment and may
require the higher risk combination of PD-1 and CTLA-4 immunotherapy for a sustained
response [107]. The need for clinical biomarkers is underpinned by two key requirements: i) to
determine patients who will need more intensive therapies to elicit positive outcomes, and ii)
to prevent the overtreatment of patients where a positive outcome can be derived from antiPD1 monotherapy. Numerous biomarkers have been explored for their ability to predict
response to immunotherapy and long-term survival [131, 138, 142, 148]. However, all
currently available markers require an invasively acquired tumour sample and are controversial
in the accuracy of predicting response.
The reality is that tumours are not always accessible, therefore are not biopsied. The
applicability of a liquid biopsy overcomes the requirement of a tumour biopsy and allows the
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real-time tracking of disease with minimal burden on the patients. The analysis of EVs and
their molecular cargo is a developing realm of research and may provide an accessible
biomarker to aid treatment selection and monitoring of resistance. The studies presented in this
thesis explore the role of melanoma EVs in transferring drug resistance and as a biomarker to
predict response to PD-1 immunotherapy.

Hypothesis
Melanoma-derived EVs carry unique molecular cargos relevant to patient treatment outcomes.

Aims
Aim 1: To evaluate whether melanoma-derived EVs carry BRAF splicing variants.
Aim 2: To investigate whether melanoma-derived EVs can transfer BRAFi resistance.
Aim 3: To determine whether the RNA cargo of EVs from the plasma of melanoma patients
can serve as a predictor of response to immunotherapy.
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CHAPTER 2:
Detection of BRAF splicing variants in plasma-derived
cell-free nucleic acids and extracellular vesicles of
melanoma patients failing targeted therapy therapies.
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2.1 Abstract
The analysis of plasma circulating tumour nucleic acids provides a non-invasive approach to
assess disease burden and the genetic evolution of tumours in response to therapy. BRAF
splicing variants are known to confer melanoma resistance to BRAFi. We developed a test to
screen cell-free RNA (cfRNA) for the presence of BRAF splicing variants. Custom droplet
digital PCR assays were designed for the detection of BRAF splicing variants p61, p55, p48
and p41 and then validated using RNA from cell lines carrying these variants. Evaluation of
plasma from patients with reported objective response to BRAF/MEK inhibition followed by
disease progression was revealed by increased circulating tumour DNA (ctDNA) in 24 of 38
cases at the time of relapse. Circulating BRAF splicing variants were detected in cfRNA from
3 of these 38 patients; two patients carried the BRAF p61 variant and one the p55 variant. In
all three cases the presence of the splicing variant was apparent only at the time of progressive
disease. BRAF p61 was also detectable in plasma of one of four patients with confirmed BRAF
splicing variants in their progressing tumours. Isolation and analysis of RNA from extracellular
vesicles (EV) from resistant cell lines and patient plasma demonstrated that BRAF splicing
variants are associated with EVs. These findings indicate that in addition to plasma ctDNA,
RNA carried by EVs can provide important tumour specific information.
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2.2 Introduction
Mutations in the serine/threonine kinase BRAF are found in 40% of melanomas [221]. The
most prevalent mutation in melanoma is BRAF V600E, which constitutively activates
downstream mitogen-activated protein kinase (MAPK) signalling. Introduction of single agent
BRAF mutant inhibitors (BRAFi), such as vemurafenib and dabrafenib, revolutionised the
treatment of metastatic melanomas [29, 30]. Furthermore, the combination of BRAF and MEKi
(such as dabrafenib and trametinib, or vemurafenib and cobimetinib) improved tumour
response rate and progression-free survival, while attenuating some of the serious adverse
events observed with monotherapy [37, 222]. However, even with combination therapies,
resistance to MAPK inhibition remains a major challenge in clinical care, with the majority of
patients progressing within 10 months [223]. Identification of the mechanism of resistance to
targeted therapies in individual patients may offer new insights into strategies for overcoming
resistance.
Resistance to BRAF inhibitors usually involves MAPK reactivation, via mutations in NRAS or
MAP2K1/2, upregulation of RTKs, mutant BRAF gene amplification or alternative BRAF
splicing [76, 77, 79, 224]. In around 30% of resistant tumours, resistance to BRAF inhibition
is conferred by alternative splicing via generation of BRAF isoforms lacking the RAS binding
domain (RBD) encoded by exons 3–5 [79, 225]. In the absence of the RBD, these BRAF
isoforms dimerise even in the presence of low levels of RAS, conferring and conferring
resistance to BRAF inhibition [87]. Four BRAF splicing variants, referred to as p61, p55, p48
and p41 were named based on their predicted molecular weight (Figure 2.1A).
The analysis of tumour-derived biomarkers in blood of cancer patients is transforming clinical
cancer pathology. Circulating tumour DNA (ctDNA) has emerged as a non-invasive biomarker
to track tumour burden and allow monitoring of the cancer genome in blood across several
malignancies including melanoma [226, 227]. We, and others, have previously demonstrated
that increased melanoma ctDNA levels and the appearance of circulating mutations associated
with of acquired resistance, provide highly specific, early information of relapse during BRAF
targeted therapies [121, 151]. The latter supports a clinical model that incorporates the analysis
of ctDNA in patients undergoing BRAF-inhibitor therapies as a routine test to detect early
relapse and resistance [226, 227]. However, resistance involving aberrant splicing variants,
cannot be detected through ctDNA analysis, and can only be identified using RNA.
Circulating tumour-derived cell free RNA or circulating tumour RNA (ctRNA) can be found
in plasma from patients with cancer [228-230]. Various studies have also demonstrated the

45

ability to amplify tumour-related mRNAs from sera of patients with melanoma, breast cancer,
and other malignancies [231-235]. However, the possibility that extracellular RNA could
survive in the blood has not been widely accepted, due to plasma containing potent
ribonucleases capable of degrading cell-free RNA [236]. Regardless of this, studies have
documented the presence of ctRNA in serum/plasma of cancer patients [237, 238].
Extracellular vesicles (EVs) are known to contain various RNA types, including microRNA,
mRNA and circular RNA [239]. EV RNA has been described as having a substantial role in
the transfer and movement of epigenetic information and is stable enough for whole
transcriptome sequencing [240-242]. It is plausible that plasma cell-free RNA (cfRNA) is a
mixture of RNA protected by RNA binding proteins and RNA contained within EVs. Here we
explore whether alternative BRAF splicing variants can be detected in melanoma patients who
have developed resistance to BRAFi therapy. We report a new methodological approach based
on digital droplet polymerase chain reaction (ddPCR) to assess the presence of BRAF splicing
variants in plasma cfRNA and EV-derived RNA. We interrogated plasma from 38 melanoma
patients identified as having clinically diagnosed treatment resistance after initial response to
BRAFi monotherapy or BRAF/MEK inhibitor combination. In addition, cfRNA was
interrogated from an additional five patients who were confirmed to have tumour specific
BRAF splicing variants in their progressing tumours. Finally, we evaluated the presence of
BRAF splicing variants in EV RNA isolated from plasma of two melanoma patients failing
BRAF inhibition.

2.3 Results
Development of a sensitive assay for detection of BRAF splicing variants in Plasma
We developed ddPCR assays for the detection of alternative BRAF splicing variants: p61, p55,
p48 and p41, which are associated with resistance to BRAF inhibition, as well as the canonical
full length BRAF (pFL) (Figure 2.1A). The assays were validated using three melanoma cell
lines with resistance to BRAF inhibition and known to express alternative BRAF splicing
variants (Figure 2.1B). As previously reported, SK-Mel-28.BR4 expresses BRAF p55 (exon 410∆), SMU027 expresses BRAF p48 (exon 2-8∆) and WMD009 expresses BRAF p41 (exon
2-10∆) [76, 243]. Surprisingly without amplification all cell lines carry the BRAF p61, albeit
at lower concentrations in comparison to the dominant splice variant expressed. Similarly,
SMU027 expressed low levels of BRAF p41 compared to WMD009.
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To enhance sensitivity of detection of BRAF splicing variants, a pre-amplification step was
introduced. This resulted in a significant enhancement of the signal without loss of specificity
(Figure 2.1B). Importantly, the introduced pre-amplification step maintained a linear relation
between copies of input cDNA and output BRAF splicing variant copies (R2 =0.9986,
p<0.0001), with a 6,396 ± 569 fold increase in BRAF splicing variant copies (Supplementary
Figure 2.2).
We tested plasma from nine healthy volunteers, to confirm that the BRAF splicing variants are
not commonly found in normal plasma and that the assay does not introduce artefacts or induce
false detection of BRAF alternative splicing variants (Supplementary Figure 2.3).

Figure 2.1: BRAF splice variants detection by droplet digital PCR: A. BRAF exon
organisation of the splicing variants and location of primers and probes used for detection of
splicing variants. B. Droplet digital PCR Ch1,1D plots of each BRAF splicing detection assay
of melanoma cell lines carrying BRAF splicing variants, with and without the pre-amplification
(PreAmp) step.
Analysis of BRAF splicing variants in plasma of melanoma patients
We prospectively collected longitudinal plasma samples from 38 patients: 7 vemurafenib and
31 dabrafenib/trametinib treated cases (Supplementary Figure 2.4). Of the 7 vemurafenib cases,
2 had baseline plasma for ctDNA analysis, and of these 1 experienced a decrease in mutant
BRAF during treatment (MM143), while the other had an increase in mutant BRAF copies
during treatment (MM141). Of the 31 dabrafenib/trametinib cases, 25 had assessable baseline
plasma, and of these 24 cases had detectable ctDNA (as mutant BRAF copies) at baseline. In
47

19 of the 24 cases, ctDNA decreased during treatment in comparison to the baseline sample.
Analysis of blood samples collected at the time of progressive disease (red points –
Supplementary Figure 2.4), identified 29 patients (5 on vemurafenib and 24 on combination
dabrafenib/trametinib therapy) with detectable ctDNA at progression. Of those, six had
additional NRAS Q61 mutations and one had a BRAF gene amplification detectable in plasma
(Figure 2.2 and Supplementary Table 1).

Figure 2.2: Clinical and ctDNA profile of patients that showed clinical progressive disease
to targeted therapy: Overview of ctDNA results (copies/mL plasma) from BRAF, NRAS,
BRAF splicing and BRAF amplification in 38 melanoma patients. Each column is an individual
patient, showing their clinical characteristics, quantitative ctDNA results (copies/ml or µl of
plasma) and presence of BRAF amplification. *BRAF V600E c.1799_1800GT>AA, p.
(Val600Glu), also known as BRAF V600E2 mutation.
Three patients (MM175, MM493 and MM878) had detectable BRAF splicing variants in
plasma using our assay, indicating the presence of ctRNA. BRAF splicing variants were not
detected in the pre-treatment plasma (MM493, MM878) despite clear detectable ctDNA
(Figure 2.3). Unfortunately, no plasma collected at baseline was available from MM175 for
BRAF splicing variant assessment.
MM175 presented with multiple spine, rib and liver metastases. The patient received
dabrafenib/trametinib combination treatment and showed a partial response at 5 weeks, with
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undetectable ctDNA (Figure 2.3A). Subsequent scans confirmed progression with the patient
being moved onto ipilimumab immunotherapy. Analysis of plasma ctRNA at the final point of
dabrafenib/trametinib progression (21 weeks) and after change of therapy to ipilimumab (38
weeks), revealed that the BRAF splicing variant p55 was present only at the time of progression
but undetectable while on ipilimumab treatment, despite having sustained BRAF V600K
ctDNA levels.
MM493 presented with multiple brain, lung and abdomen metastases. One brain metastasis
was resected while and the others were treated with whole brain radiotherapy. This patient
received dabrafenib/trametinib combination treatment with partial response at 8 weeks and
limited decrease in ctDNA (Figure 2.3B). BRAF p61, but no other BRAF splicing variants, was
detected at the time of progression (17 weeks, Figure 2.3B). Plasma collected at baseline,
during response (10 weeks) or after starting pembrolizumab (25 weeks) did not have detectable
BRAF splicing variants. BRAF V600E ctDNA was detectable in this patient at all four-time
points analysed but became undetectable by week 54 in response to treatment with
pembrolizumab.
The third patient (MM878) presented with widespread melanoma in lung, lymph node, adrenal,
bone and gallbladder. The patient was placed on dabrafenib/trametinib combination treatment
and a partial metabolic response was observed 5 weeks later which was concordant with a
decrease from 458 copies/ml to 56 copies/ml decrease in BRAF V600E ctDNA (Figure 2.3C).
At the time of progression additional skeletal metastases were observed by PET scan 18 weeks
into therapy, with ctDNA levels significantly increased to 458 copies/ml, with the PET scan
confirming progression of several skeletal metastases. The BRAF p61 variant was detectable
in plasma at the point of progression but was undetectable at baseline or the first follow up
sample collected 4 weeks into therapy (Figure 2.3C).
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Figure 2.3: Detection of splice variants in the combination therapy cohort: Three patients
undergoing combination BRAFi therapy were positive for a splicing variant. A. Patient
MM175 was positive for the p55 variant while B. patient MM493 and C. patient MM878, were
both positive for the p61 variant at the point of progressive disease shown in the droplet digital
plots.. The longitudinal graphs represent the ctDNA tracking of the activating mutation for the
patients. Green, red and grey dotted lines represent clinical response, progressive disease and
stable disease respectively. The singular red dot represents the time-initial point tested positive
for the splicing variants and neighbouring time-points were tested to confirm the presence or
absence of the splicing variants. The coloured area indicates the period during which systemic
therapy was administered; colours representing dabrafenib/trametinib (yellow), ipilimumab
(red) and pembrolizumab (blue). Droplet digital plot represents the positivity for the indicated
BRAF splicing variant (blue dots). BRAF full length (BRAF FL, green dots) was use as
positive control for RNA extraction and amplification. No template control and positive control
(SK-Mel-28.BR4) were included in each test.
To validate our findings, we next tested the plasma derived from five melanoma patients that
were treated with vemurafenib monotherapy who developed resistance. Tumour samples
obtained at the time of progression had confirmed BRAF splicing variants by transcriptome
analysis [224] (Figure 2.4). We analysed plasma samples from these patients collected near the
time of resecting the progressed tumour. Only one of these five cases (MIA_10) had a
detectable splicing variant (BRAF p61) in plasma which was concordant with the results of the
matched tumour sample. BRAF splicing variants were not detectable in the baseline plasmas
from theses patient.
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Figure 2.4: Detection of BRAF spice variants in patients known to have the splice variant:
A. Patients who had confirmation of splicing variants in the tumour were investigated to
confirm the presence of the variant in the plasma. B. The droplet digital plot represents the
positivity for p61 in one of the samples.
BRAF splicing variants are associated with extracellular vesicles
Plasma extracellular RNAs are thought to be carried by extracellular vesicles [244]. To
evaluate whether BRAF splicing variants are found in EVs, we analysed extracellular vesicles
extracted from the plasma of patients MM493 and MM878. EVs isolated from the supernatant
of SK-Mel-28.BR4 cell line and from the plasma of a healthy control were used as positive and
negative controls, respectively.
The effective isolation of EVs was confirmed by western blot analysis, with positive signal for
the tetraspanins CD9, CD63, CD81 and Tumour Susceptibility Gene 101 (TSG101), while
negative for the cellular marker calnexin (Figure 2.5A). Transmission electron microscopy
(TEM) was used to visualise the extracted EVs, demonstrating the presence of exosomes with
a size of 100nm (Figure 2.5B). Analysis of EV RNA from SK-Mel-28.BR4 cells confirmed the
presence of BRAF p61 and BRAF FL, while EV RNA from healthy volunteer only carried
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BRAF FL variants. EV RNA from both MM493 and MM878 contained BRAF p61 transcripts
(Figure 2.5C).

Figure 2.5: Validation of EV isolation from exo-easy and confirmation of splicing variant
presence: A. EVs isolated using the ExoEasy Kit were tested for the associated markers TSG101, CD81, CD9 and CD63 and the negative marker Calnexin. Loading was standardised at
4µg across all EVs preparations. B. Electron micrographs were used to determine the presence
of EV/exosomes in the appropriate size range. C. Droplet digital testing for BRAF p61 (blue
dots) and FL-BRAF (green dots) in EV-derived RNA from the patients, healthy controls and
cell line SK-Mel-28.BR4.

2.4 Discussion
The emergence of BRAF splicing variants is a common mechanism of escape to BRAF
inhibition in melanoma [77, 87]. Elucidation of the molecular escape mechanisms usually
requires the sourcing of tumour tissue at the time of progressive disease. Here we show that
tumour specific splicing variants, known to mediate treatment resistance, can be detected in
plasma.
Our study demonstrated the detection of resistance mediating BRAF splicing variants in ctRNA
of melanoma patients failing BRAF inhibiting therapies. Moreover, we showed that these
BRAF splicing variants are co-purified or associated with EVs.
The frequency at which we detect splicing variants in this cohort was low. Tumour analyses
within cohorts treated with BRAF inhibiting monotherapies suggest a prevalence of
approximately 30% for splicing variants [77, 224]. Long et al. suggested that BRAF splicing
were unlikely to occur in combination therapy as MAPK signalling driven by such variants
will require MEK activity and therefore will remain sensitive to MEKi [76, 91]. Nevertheless,
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we did not detect BRAF splicing variants in any of the 7 patients treated with vemurafenib
monotherapy. In contrast, we observed BRAF splicing variants in 3 of 31 patients treated with
combination BRAF/MEK inhibitors. A study by Wagle et al., reported the detection of BRAF
p41 in the post-treatment tumour of 1 out of 5 patients that developed resistance to
dabrafenib/trametinib [90].
In this study, we failed to detect BRAF splicing variants in 4 of 5 patients for which the tumours
were confirmed to carry BRAF splicing variants by tissue analysis. The isolation and presence
of circulating RNA was confirmed in all samples through the presence of BRAF full length.
Moreover, we showed that our method had high analytical sensitivity and specificity. However,
several technical and biological reasons may explain the low clinical sensitivity of the test.
Similar to ctDNA, ctRNA detection is likely to be affected by tumour burden, metabolic
activity and location of the tumour [157, 245] . In addition, pre-analytical conditions have not
been optimised for the preservation and extraction of ctRNA or EV-derived mRNA in the same
way that it has been done for ctDNA [246].
The presence of ctRNA has been previously reported in plasma and other body fluids of cancer
patients [228, 247-249]. Early reports published by Lo et al. [250] indicated the presence of
tumour derived ctRNA in the plasma of nasopharyngeal carcinoma patients. Beyond this,
ctRNA analysis has been expanded primarily into cancer detection cancer or monitoring
response [251]. For example, plasma ctRNA expression of the carcinoembryonic antigen has
been used for diagnosis of early stage prostate cancer [251] and plasma TERT mRNA levels
have demonstrated to be predictive of response to chemoradiotherapy in rectal cancers [252].
Thus, ctRNA shows promise as an additional monitoring tool that can be used in combination
with ctDNA and conventional methods. The advantage of ctRNA is implied through the
assessment of transcriptional activity of genes.
The effective isolation of EVs was validated using western blot and transmission electron
microscopy. Purity was confirmed through negativity of calnexin, along with the positivity of
CD9, CD63, CD81 or TSG101 which are EV associated proteins [177]. Patient MM828-EV
sample was CD81 negative but positive for the other markers, demonstrating that reliance on
one or two markers poses a risk of false negativity. The heterogeneity of EV-associated proteins
has been reported previously [253-255], suggesting that a panel of markers is required to
validate the presence of EVs.
EVs have been established as carriers of various types of RNA, including mRNA, miRNA and
long non-coding RNAs [256-258]. The EV RNA from the patients MM493 and MM878 were
found positive for BRAF-p61, matching the results obtained via their plasma ctRNA. This
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suggests that ctRNA may be carried totally or partially by EVs, and that these vesicles may be
protecting RNA from degradation [256, 259, 260].
Alterations on splicing variants have been shown to be associated with cancer progression and
treatment resistance [261]. Splicing variants of the androgen receptor, in particular AR-V7,
have been found to be significantly higher in hormone refractory prostate cancer and is
associated with poor clinical outcomes [262]. Similar to BRAF-splicing variants, AR-V7 can
be detected in plasma EV RNA [260, 263]. Altogether, this supports an alternative liquid
biopsy modality based on EV RNA or ctRNA.
Liquid biopsies have emerged as a non-invasive approach to assess disease burden and the
genetic evolution of tumours in response to therapy [121, 150, 264, 265]. Our study provides
a foundation for the detection of splicing variants in both ctRNA and EV RNA in melanoma
patients failing MAPK inhibition, although its clinical validity requires further evaluation in
independent cohorts. This work constitutes an important proof of concept that in addition to
plasma ctDNA, ctRNA can provide important tumour specific information related to the
development of resistance. However pre-analytical conditions for ctRNA analysis still require
optimisation to enable its clinical application.

2.5 Methods
Patient selection
A total of 38 participants with BRAF mutant metastatic melanoma were treated with
vemurafenib or with dabrafenib and trametinib combination as per approved label were
enrolled (Supplementary Table 2.1). Patients were required to have a recorded objective
response to therapy, either partial or complete confirmed by CT or PET scans. All patients gave
their signed informed consent before blood collection and data analysis. The study was
performed in accordance with the Declaration of Helsinki and study protocols were approved
by the Human Ethics Committees at Edith Cowan University (No.11543) and Sir Charles
Gardner Hospital (No.2013-246).
Plasma from another five patients treated recruited at the Melanoma Institute Australia and
affiliated hospitals were included in this study (Melanoma Institute Australia Biospecimen
Bank for Melanoma Research X11-0289 & HREC/11/RPAH/444 approved through Sydney
Local Health District). These patients were selected as they were previously identified as to
have BRAF splicing variants in their progressing tumour after failing treatment with dabrafenib
monotherapy.
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Cell Culture
Melanoma cell line 451Lu was obtained from the Wistar Institute. SK-Mel-28.BR4, SMU027
and WMD009 were previously reported to carry BRAF splicing variants [76, 243]. All cell
lines were cultured in Dulbecco’s Modified Eagle Medium (DMEM) (Thermo Fisher
Scientific, Carlsbad, CA) supplemented with 10% Foetal Bovine Serum (Thermo Fisher
Scientific, Carlsbad, CA) at 37°C and 5% CO2.

RNA extraction from cell lines
RNA was extracted using the AllPrep DNA/RNA Mini kit (Qiagen, Hilden, Germany)
according to the manufacturer’s instructions. RNA was eluted in RNAse free water and stored
at -80 °C until analysis.

Circulating nucleic acid extraction
Blood samples were collected into EDTA vacutainer tubes and plasma was separated within
24 hours by centrifugation at 300 g for 20 minutes, followed by a second centrifugation at 4700
g for 10 minutes and then stored at -80oC until extraction. Plasma cell-free nucleic acids (cfNA)
were isolated from healthy donors and AJCC stage IV metastatic melanoma patients using the
QIAamp Circulating Nucleic Acid Kit (Qiagen, Hilden, Germany) as per the manufacturer’s
instructions. cfNA was eluted in 40 µl AVE buffer (Qiagen, Hilden, Germany) and stored at 80oC.

Reverse transcription and preamplification
Extracted RNA (5 µl) from all samples were used for cDNA preparation using the
SuperScript® VILO™ cDNA Synthesis Kit (Thermo Fisher Scientific, Carlsbad, CA)
followed by a preamplification using the TaqMan® PreAmp Master Mix Kit (Thermo Fisher
Scientific, Carlsbad, CA) and all the primers for the BRAF splicing variants at 180 nM,
following manufacturer cycling conditions (95°C for 10 minutes, followed by 14 cycles of
95°C for 15 seconds and 60°C for 4 minutes, with a final inactivation step at 99°C for 10
minutes). Linearity of the pre-amplification step was assessed by linear regression of a serial
dilution curve (Supplementary Figure 2.2).

Droplet digital PCR
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Primer pairs were designed to amplify over the unique exon-exon junction of each splicing
variant, with probes overlapping the junction (Figure 2.1A and Supplementary Table 2.2).
Probes were custom synthesised by Integrated DNA Technologies (IDT, San Jose, CA, USA).
For ctDNA analysis, samples were analysed for the presence of BRAF or NRAS mutant DNA
as described previously [121, 266].
Amplifications were performed in a 20 µL reaction containing 1x ddPCR Supermix for Probes
(No dUTP, Bio-Rad), 1x Q solution (Qiagen, Hilden, Germany), 250 nM of each probe and
900 nM of each primer plus template. Droplets were generated using the automatic droplet
generator QX200 AutoDG (Bio-Rad, Hercules, CA, USA). Amplifications were performed
using the following cycling conditions: 1 cycle of 95°C (2.5C/s ramp) for 10 minutes, 40 cycles
of 94°C (2.5C/s ramp) for 30 seconds and 55°C for 1 minute, followed by 1 cycle of 98°C
(2.5C/s ramp) for 10 minutes. Droplets were analysed through a QX200 droplet reader (BioRad, Hercules, CA, USA). QuantaSoft analysis software (Bio-Rad, Hercules, CA, USA) was
used to acquire and analyse data.

BRAF amplification analysis
We optimised a ddPCR assay to assess the presence of BRAF amplifications using plasmaderived cfDNA. BRAF copy number was assessed relative to a reference gene situated in the
centromere of chromosome 7 (VOPP1 gene, 7p11.2). For the assessment of BRAF:VOPP1
ratio, a ddPCR assay was performed with the Bio-Rad QX200 system using custom
primers/probe sets against BRAF [266] and VOPP1 (Bio-Rad, Hercules, CA, USA). The
BRAF:VOPP1 concentration ratio was determined by dividing the BRAF concentration by the
VOPP1 concentration offered by the QuantaSoft software (Bio-Rad, Hercules, CA, USA).
We first determined the optimal threshold to define an elevated plasma DNA ddPCR
BRAF:VOPP1 ratio using a standard curve of genomic DNA extracted from healthy volunteer
WBC combined with different percentages of genomic DNA extracted from a melanoma cell
line with known BRAF amplification (Supplementary Figure 2.1). Plasma-derived cfDNA from
six healthy volunteers were used to evaluate specificity. Patient samples with mutant BRAF
frequency abundance of 3% or higher were tested for BRAF amplification.

Extracellular vesicle isolation
For EVs isolation, cell lines at 50% confluence were washed three times with PBS and cultured
in DMEM supplemented with exosome-depleted FBS (Thermo Fisher Scientific, Carlsbad,
CA) for 18 hours at 37°C and 5% CO2. Following this, cell culture media was harvested and
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centrifuged at 300 g for 5 minutes at 4°C. The supernatant was then transferred to a clean tube
and re-centrifuged at 2000 g for 20 minutes. Cleared supernatant was used for EV isolation
using the ExoEasy kit (Qiagen, Hilden, Germany) following manufacturer’s instructions. EVs
were also isolated from 4 ml of plasma from melanoma patients and heathy volunteers using
the ExoEasy kit (Qiagen) RNA was isolated from the extracted EVs using the RNeasy Micro
Kit (Qiagen, Hilden, Germany) following manufacturer’s instructions. RNA was eluted in 14
µL.

Western Blot
SK-Mel-28 cell lysate was prepared to be used as positive control. Cells were harvested using
trypsin EDTA (Thermo Fisher Scientific, Carlsbad, CA). Cell viability was then determined
using trypan blue. Cells were then pelleted at 300 g for five minutes, washed twice in PBS and
lysed with radioimmunoprecipitation (RIPA) assay buffer (Sigma-Aldrich, St. Louis, Missouri)
containing a complete protease inhibitor tablet (Roche, Basel, Switzerland). Cell lysates were
incubated for 30 minutes on ice prior to being cleared with a 13,000 g spin for five minutes,
with the supernatant being transferred into a clean tube and stored at -20°C until use.
EV pellets were resuspended in PBS prior to mixing 1:1 with RIPA (Sigma-Aldrich, St. Louis,
Missouri) supplemented with protease inhibitor cocktail (Roche, Basel, Switzerland). EV
lysates were incubated for 30 minutes on ice and then stored at -20°C until use. Extracted EV
proteins were diluted to 1:4 in Lamelli Buffer (Bio-Rad, Australia), incubated at 95 °C for
5 minutes and resolved on a mini TGX 8-16% stain free gel (Bio-Rad). Proteins were
transferred onto a nitrocellulose blotting membrane using the Trans-Blot® Turbo™ Transfer
System at a constant voltage of 25V for seven minutes (Bio-Rad, Australia). The membranes
were blocked in 5% milk tris buffered saline (TBS) for one hour at room temperature before
being probed with primary antibody TSG101 (1:1000, clone EPR7130B, Abcam), CD9 (1:500,
clone MM2/57, Life-Technologies), CD81 (1:500, clone 1.3.3.22, Life-Technologies). CD63
(1:1000, clone H5C6, BD-Biosciences, calnexin (1:500, clone AF18, Life-Technologies)
diluted in 0.5% milk TBS 0.05% Tween 20. The membrane was washed three times for ten
minutes with TBS 0.05% tween and subsequently probed with secondary antibodies (sheep
anti-mouse IgG-HRP conjugate, polyclonal, 1:2000, GE Healthcare, donkey anti-rabbit IgGHRP conjugate, polyclonal, 1:2000, GE Healthcare) diluted in 0.5% milk TBS .05% Tween
20. Signals were detected with the GE healthcare Amersham™ ECL™ reagent and were
subsequently imaged using the ChemiDoc™ Touch Imaging System (Bio-Rad, Hercules, CA,
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USA). Images were processed using Image Lab™ software v6.0 (Bio-Rad, Hercules, CA,
USA).

Transmission electron microscopy
EVs were resuspended in PBS and fixed in 2% paraformaldehyde prior to transfer onto 200
mesh Formvar-carbon coated copper grids (ProSciTech, Kirwan, QLD). EVs were adsorbed
for 15 minutes at room temperature prior to being washed four times in filtered H2O. Samples
were then fixed in 1% glutaraldehyde and contrasted with 1% uranyl acetate for 2 minutes
before being left for 20 minutes to dry at room temperature. EVs were visualised using JEOL
JEM-2100 electron microscope (JEOL, Tokyo, Japan) at an operating voltage of 80 kV. Images
were captured using an 11M pixel Gatan Orius digital camera (Gatan, Pleasanton, CA).
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2.8 Supplementary Material
Supplementary Table 2.1. Progressive disease samples analysed for the presence of BRAF
splicing.
Patient ID

Date of
Collection

BRAF
mutation

Combination therapy (Dabrafenib/Trametinib)
MM475
2/11/2016
BRAF V600R
MM783
29/03/2019
BRAF V600E
MM149
1/04/2014
BRAF V600K
MM523
26/09/2017
BRAF V600E
MM878
10/10/2018
BRAF V600E
MM170
19/03/2014
BRAF V600E
MM1033
30/01/2019
BRAF V600K
MM802
23/01/2018
BRAF V600E
MM306
21/09/2015
BRAF V600E
MM148
22/10/2013
BRAF V600E
MM776
27/03/2018
BRAF V600K
MM958
3/12/2018
BRAF V600E
MM230
4/11/2014
BRAF V600R
MM056
15/06/2016
BRAF V600E
MM493
3/08/2016
BRAF V600E
MM525
14/02/2019
BRAF V600E
MM908
20/09/2018
BRAF V600K
MM853
18/07/2018
BRAF V600R
MM785
21/09/2018
BRAF V600E
MM636
14/02/2018
BRAF V600E
MM175
19/03/2014
BRAF V600K
MM377
13/05/2016
BRAF V600E
MM974
12/04/2019
BRAF V600E2
MM430
30/03/2016
BRAF V600K
MM895
20/02/2019
BRAF V600E
MM483
27/02/2017
BRAF V600E
MM423
8/02/2017
BRAF V600E
MM514
12/10/2016
BRAF V600E
MM469
31/08/2016
BRAF V600E
MM154
1/07/2015
BRAF V600E
MM153
15/04/2014
BRAF V600E
Vemurafenib
MM035
11/04/2013
BRAF V600E
MM107
10/04/2013
BRAF V600K
MM001
27/11/2013
BRAF V600E
MM056
10/11/2014
BRAF V600E
MM141
19/03/2014
BRAF V600E
MM069
10/04/2013
BRAF V600E
MM143
4/09/2013
BRAF V600E

ctDNA
(copies/ml)

Fractional
abundance

NRAS
mutation

196800.0
1380
1020.0
556
458
308.0
292
222
202.0
143.0
106
64.0
62.0
60.0
58.0
36.7
21.1
20
18
16
15.8
12.8
8.8
1.8
0.0
0.0
0.0
0.0
0.0
0.0
0.0

96.3
28.8
11.5
19.7
13.1
14.8
4.2
12.4
3.1
5.3
5.3
6.40
0.8
4.4
1.0
0.6
2.2
0.3
0.6
1.2
0.8
0.14
0.22
0.5
0.0
0.0
0.0
0.0
0.0
0.0
0.0

Neg
Neg
Q61K/H/R
Neg
Neg
Q61R
Neg
Neg
Neg
Q61K
Q61H/K/L/R
Q61K
Neg
Neg
Neg
Neg
Neg
Neg
Q61H
Neg
Neg
Neg
Neg
Neg
Neg
nt
nt
nt
nt
nt
nt

174
135
46.5
14.0
13.5
0.0
0.0

6
4.9
3.8
0.5
2
0.0
0.0

neg
neg
nt
neg
neg
nt
nt

ctDNA
(copies/ml)

Fractional
abundance

67.5/9

0.66/0.03

30.0

1.2

2.8
62.3

0.0
1.8

30.0

2.0

54.0

1.7

BRAF
Amplification*

BRAF
Splicing

6.6
nt
nt
nt
nt
nt
nt
nt
nt
nt
nt
nt
nt
nt
nt
nt
nt
nt
nt
nt
nt
nt

BRAF p61
BRAF p61
BRAF p55
-

nt
nt
nt
nt
nt
nt
nt

-

BRAF
splicing
(copies/µl)

21.5

153

53.5

nt- not tested, * BRAF amplification expressed as a ratio of BRAF copies/VOPP1 copies
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Supplementary Table 2.2 Primers and probes for detection of BRAF splicing variants.
Length
(bp)

Tm (˚C)

AATTGCATGTGGAAGTGTTG

20

60.97

GCTTTCGACAAAAGTCACAA

20

60.75

BRAF-p61-Forward

TCACCACAAAAACCTATCGT

20

61.03

BRAF-p61-Reverse

CACGAAATCCTTGGTCTCTA

20

60.74

BRAF-p55–Reverse

AATCTGCCCATCAGGAAT

18

60.23

BRAF-p48-Forward

TTCAACGGGGACATGGA

17

62.77

BRAF-FL

/5-HEX/CACACAACT/ZEN/TTGTACGAA/3IABkFQ/

18

56.71

BRAF-p61

/56-FAM/AGGACAGTG/ZEN/GACTTGATT/3IABkFQ/

18

59.6

BRAF-p55

/56-FAM/TACCAAGTG/ZEN/TTTTCACTGTCCTC/3IABkFQ/

23

64.06

BRAF-p48

/56-FAM/ATCAAGTCC/ZEN/TCCTCCGGA/3IABkFQ/

18

64.1

BRAF-p41

/56-FAM/CCAAGTGTT/ZEN/TTCTCCTCCGG/3IABkFQ/

20

64.97

Name

Sequence

BRAF-FL-Forward
BRAF-FL-Reverse
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Assay Sensitivity Curve
5

Ratio (a/b)

4

3

2

1

0
0%

0.39%

0.78%

1.56%

3.12%

6.25%

12.5%

25%

50%

Fractional Abundance

Supplementary Figure 2.1. Sensitivity curve of the BRAF amplification assay. Relationship
of ratio and variable fractional abundance of cell line mixtures. Clinical samples with ≥3%
BRAF mutant FA were tested for BRAF amplification.
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A

B

C

D

Supplementary Figure 2.2. Linearity of BRAF pre-amplification. A: 1D plots of ddPCR
specific for BRAFp55 with increasing cDNA input with and without prior pre-amplification.
B: Copies per well output from ddPCR. The error bars indicate the upper and lower limit of
Poisson each result. C: Linear regression of cDNA copies prior to and after pre-amplification.
The R2 value of the analysis is indicated. Error bars of three replicates are indicated for each
dilution. D: Fold change for each one of the concentrations, with error bars for each dilution
indicated.
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Sex

Age

Ctrl 1

Male

54

Ctrl 2

Male

41

Ctrl 3

Female

48

Ctrl 4

Female

47

Ctrl 5

Female

48

Ctrl 6

Female

41

Ctrl 7

Female

52

Ctrl 8

Male

58

Ctrl 9

Male

51

Supplementary Figure 2.3. Specificity of BRAF splicing variants detection in plasma. Cell
free nucleic acid isolated from plasma of 9 healthy individuals were tested for all four BRAF
splicing variants and full length BRAF. Only full length BRAF (green) was detected in all 9
healthy control samples. Age and sex of all the donors are specified in the inserted table.
Positive control constitutes a mix of RNA from cell lines expressing the corresponding variant
as sown in Figure 1B: SKMel-28.BR4 (p61 and p55), SMU027 (p48) and WMD009 (p41).
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Supplementary Figure 2.4. Monitoring ctDNA levels during clinical disease course. A-B,
Plasma ctDNA concentrations for patients that progressed on dabrafenib/trametinib (A) or
vemurafenib (B). Radiological outcomes such as, response, stable disease, mixed response and
progressive disease are represented by a dashed green, orange, gray, or red line, respectively.
A black dashed line represents time of death and indicated with a black cross (†). The coloured
area indicates the period during which systemic therapy was administered; colours
representing dabrafenib/trametinib, nivolumab, ipilimumab, vemurafenib, pembrolizumab,
ipilimumab/nivolumab, vemurafenib/cobimetinib, dabrafenib, DTIC, bevacizumab.
#
Intracranial disease progression with no extracranial involvement.
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Supplementary Figure 2.5. Uncropped images from western blots shown in Figure 5A.

66

CHAPTER 5:
General discussion, conclusions, and future directions
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Within the last decade, there has been an expanded interest in the research of EVs with regards
to their role as intercellular communicators and their potential as cancer biomarkers. The
studies in this thesis summarise research on melanoma-associated EVs. In particular, the
studies revealed that plasma EVs can potentially provide tumour specific information that
could inform clinical decisions relevant to drug resistance and response to treatment. In
addition, an exploratory study to evaluate the potential of EVs on the transfer of resistance to
BRAFis was performed. Overall, the results provide insight into the potential role of EVs as a
novel melanoma biomarker.
EVs have been progressively implicated in the mediation of drug resistance across multiple
cancers. As discussed, EVs can transfer resistance mediators such as RNA species (mRNA,
lncRNA and microRNAs) or functional proteins (p-glycoprotein) [218, 267-272]. The potential
of EVs as carriers of resistance may offer two clinically relevant paradigms, i) they could serve
as biomarkers for early detection of resistance; and ii) therapies to block EV-mediated transfer
of resistance could be implemented as combination treatments, with the aim of improving
outcomes. In addition, the early detection of resistance prior to treatment failure could mitigate
disease progression through the adaptation of other treatment strategies, maximising patient
outcomes [273, 274].
The work completed within Chapter 2 demonstrates, for the first time, the ability to detect
BRAF splicing variants in plasma cfRNA and EVs of melanoma patients failing targeted
therapy. The role of BRAF splicing variants as mediators of resistance was initially described
by Poulikakos et al. in melanoma patients progressing on vemurafenib [87]. Larger studies of
patients failing BRAF targeted therapy confirmed the presence of BRAF splicing variants in
the resistant tumours [77, 224]. In contrast to the detection of these variants in tumour tissue,
the work presented in this thesis demonstrated the ability to detect BRAF splicing variants in
plasma, a substantially more accessible approach.
To assess the potential of EVs as carriers of BRAF splicing variants in plasma, EVs from the
plasma of patients confirmed to have these variants in plasma cfRNA were evaluated. The
presence of BRAF splicing variants in RNA isolated from plasma EVs was unequivocally
established. Notably, RNase treatment of EVs prior RNA isolation was not performed as shown
by others previously [275-278]. Therefore, it is possible that the splicing variants were extravesicular in nature. Nevertheless, this outcome does not detract from the ability to detect
splicing variants either through cfRNA, co-purified or contained within EVs. Further
evaluation is required for both the confirmation that EVs carry these variants and that the pre-
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enrichment of EVs improves these assays' sensitivity. This study was unable to assess this, as
only two patients positive for splicing variants had sufficient plasma available for EV isolation.
The presence of cancer-related splicing variants in tumour-derived EVs has been described
previously [279, 280]. The detection of splicing variants contained within EVs as biomarkers
has been pioneered in prostate cancer through screening for AR-V7 variants in plasma EVderived RNA [260, 263]. Splicing variants of AR, such as AR-V7 and AR-V9, have been found
to be significantly higher in hormone refractory prostate cancer and is associated with poor
clinical outcomes [262]. More recently, Fettke et al. showed that the presence of AR splice
variants in plasma derived RNA, together with other AR genetic aberrations, is associated with
poor outcomes of metastatic castration-resistant prostate cancer patients on available drug
treatments. Supported by these prostate cancer studies, the findings in Chapter 2 demonstrate
a new method to detect BRAF splicing events, underscoring new information that can be
provided through RNA analyses utilising non-invasive approaches.
The establishment that EVs can carry mediators of resistance, led to the investigation of EVs
as a transferrer of drug resistance between melanoma cells in Chapter 3. Transfer of resistance
by EVs in other cancers has widely been attributed to the movement of the multidrug resistance
mediator P-glycoprotein [281, 282]. Further studies have shown the transfer by EVs of different
types of mediators in the form of proteins and RNA species [269, 270, 283-288]. Previously,
Vella et al. demonstrated that EVs can mediate resistance to BRAFi in melanoma by delivering
the RTK PDGFRβ [206]. As discussed in Chapter 1, melanoma has multiple mechanisms to
overcome BRAF inhibition. Thus, we sought to expand and evaluate the capacity of EVs to
transfer other resistant mediators for their capabilities in preventing cell death. The work
presented in Chapter 3 utilised the parental cell line SK-Mel-28 along, with the three resistant
derivatives BR2, BR4 and BR9, to evaluate the ability of these resistant lines to transfer
materials that can instigate BRAFi/MEKi resistance in-vitro. Preliminary work determined that
the mixture of parental cells with BR2 or BR9 improved the survival of the sensitive cells.
Minor growth benefits were observed when providing EVs to sensitive cells. However, no
protection from MAPK pathway inhibition was offered by transferring EVs from resistant cells.
Given the complexities of the experimental models to evaluate the transfer of resistance,
several factors could have influenced the outcomes of the study. As discussed in Chapter 3,
multiple conditions should be altered to re-assess the abilities of EVs as a resistance mediator.
For example, high concentrations of the BRAFi may exceed the equimolar balance required
for protection that resistant derived EVs could provide. Thus, analysis of a broader range of
concentrations need to be evaluated in the future. Moreover, additional effects of resistant cell69

derived EVs over other proliferative pathways, such as PI3K-AKT should have been evaluated
to discard MAPK independent resistance. Furthermore, the dynamics required to achieve a
drug resistant effect are not truly known, and it may be a requirement that a continuous delivery
of EVs is essential to sustain resistance. In addition, the dosage of EVs may be insufficient to
propagate resistance throughout the sensitive cells.
Numerous landmark studies have revealed the potential of EVs as predictors of patient
outcomes. The primary focus within EVs has been the possibility of profiling circulating RNA
species. Few studies have assessed plasma-derived EV mRNA from cancer patients, with most
studies focusing on miRNA profiling [256-258, 260, 279, 289, 290]. Within this thesis, Chapter
2 demonstrated the capability of isolating RNA from plasma EVs, using a column-based
method (exoEasy kit), and showed the presence of tumour-derived RNA species through the
detection of mutant BRAF and BRAF splicing variants. The work described in Chapter 4 built
on this research to evaluate the predictive value of plasma-derived EV-mRNA from late-stage
melanoma patients commencing immunotherapy with pembrolizumab.
Circulating EV transcriptome profiling determined a set of genes upregulated in patients that
respond to immune checkpoint inhibitors. Pathway analysis established that these genes were
involved in immune-related process, particularly concerning B-cells.
The identification of genes relating to activated B cells in circulating EVs as a biomarker of
response was revealing, as the role of B cells in the response to ICI has been only recently
established [291-293]. The density of B cells within TLS correlates with protective immunity,
and provide clinical benefit from immunotherapy for patients with lung cancer and sarcoma
[294, 295]. Moreover, an increased presence of TLS have profound long-term benefits to
overall patient survival in lung cancer [296]. Thus, the potential of the B-cell associated, EVderived gene sets identified in this study to predict response to pembrolizumab is an exciting
finding. Clinically no circulating markers are used to identify melanoma patients who will
respond or fail immune checkpoint inhibition. Although an excellent prospect, further
validation work is essential to confirm this panel of markers before it can be used clinically.
Notably, this pilot study only included 17 patients treated with pembrolizumab and primarily
consisted of patients responding to therapy patients. Only 35% of the cohort showed no
response, compared to the 61-66% observed in other clinical studies [107, 111]. Thus, this bias
may have affected the genes identified in our analysis, due to non-responders being poorly
represented. This underscores the need for validation in larger studies. Moreover, this study
only included patients treated with pembrolizumab as first-line therapy. However, melanoma
patients who are BRAF mutant may be treated with targeted therapy as first line treatment,
70

potentially altering the tumour prior to intervention with ICI. As shown for other circulating
biomarkers, prior treatment with BRAFi undermines the prognostic value of ctDNA [297].
Thus, further study is needed to evaluate the set of genes identified here in patients receiving
immunotherapy as a second line treatment to determine its broader applications.
Early works established the ability of EVs to carry major histocompatibility complexes
(MHCs) within intestinal epithelial cell derived EVs [298], and within dendritic cell derived
EVs [299, 300]. The ability to detect immune specific genes either related to TLS or an
activated immune signature that can predict therapeutic outcomes is an exciting development.
The non-cancer specific nature of these genes and the extended role of TLS in cancer survival
and response to immunotherapy, suggests that the set of genes identified here may serve as a
general indicator of response across different cancers treated with immune checkpoint
inhibitors. Extended analysis of larger patient cohorts beyond melanoma, as well as within
melanoma treated with other ICI modalities will be critical for validation.

Concluding remarks
Overall, this thesis provides and demonstrates innovative approaches in applying the utility of
extracellular vesicles within the context of melanoma. EVs are an expanding role within the
realm of both the liquid biopsy space and within the therapeutic production space.
Key methodologies have been developed based on current literature to provide a preliminary
investigation into the role of EVs as resistance mediators. Although the works presented here
are not conclusive to prove the potential actions that EVs have in fostering resistance statuses,
they provide a foundation of which further work can build upon to overcome the limitations
within the study.
Utilising a robust method for EV-RNA isolation and characterisation, this work generated an
interesting set of EV associated transcripts that can differentiate melanoma patients responding
from non-responding to ICI. Historically the search for such a set of markers has been
controversial in their applicability. This pilot study should now be expanded to include other
immunotherapy types within melanoma and potentially include other cancers that also benefit
from immunotherapy.
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EVs to mediate resistance of BRAF inhibitor therapy
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CHAPTER 4: Extracellular vesicle-derived RNA predicts
response of melanoma to PD-1 immunotherapy

CHAPTER 5:
General discussion, conclusions, and future directions
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Within the last decade, there has been an expanded interest in the research of EVs with regards
to their role as intercellular communicators and their potential as cancer biomarkers. The
studies in this thesis summarise research on melanoma-associated EVs. In particular, the
studies revealed that plasma EVs can potentially provide tumour specific information that
could inform clinical decisions relevant to drug resistance and response to treatment. In
addition, an exploratory study to evaluate the potential of EVs on the transfer of resistance to
BRAFis was performed. Overall, the results provide insight into the potential role of EVs as a
novel melanoma biomarker.
EVs have been progressively implicated in the mediation of drug resistance across multiple
cancers. As discussed, EVs can transfer resistance mediators such as RNA species (mRNA,
lncRNA and microRNAs) or functional proteins (p-glycoprotein) [218, 287, 288, 295, 342344]. The potential of EVs as carriers of resistance may offer two clinically relevant paradigms,
i) they could serve as biomarkers for early detection of resistance; and ii) therapies to block
EV-mediated transfer of resistance could be implemented as combination treatments, with the
aim of improving outcomes. In addition, the early detection of resistance prior to treatment
failure could mitigate disease progression through the adaptation of other treatment strategies,
maximising patient outcomes [345, 346].
The work completed within Chapter 2 demonstrates, for the first time, the ability to detect
BRAF splicing variants in plasma cfRNA and EVs of melanoma patients failing targeted
therapy. The role of BRAF splicing variants as mediators of resistance was initially described
by Poulikakos et al. in melanoma patients progressing on vemurafenib [87]. Larger studies of
patients failing BRAF targeted therapy confirmed the presence of BRAF splicing variants in
the resistant tumours [77, 224]. In contrast to the detection of these variants in tumour tissue,
the work presented in this thesis demonstrated the ability to detect BRAF splicing variants in
plasma, a substantially more accessible approach.
To assess the potential of EVs as carriers of BRAF splicing variants in plasma, EVs from the
plasma of patients confirmed to have these variants in plasma cfRNA were evaluated. The
presence of BRAF splicing variants in RNA isolated from plasma EVs was unequivocally
established. Notably, RNase treatment of EVs prior RNA isolation was not performed as shown
by others previously [347-350]. Therefore, it is possible that the splicing variants were extravesicular in nature. Nevertheless, this outcome does not detract from the ability to detect
splicing variants either through cfRNA, co-purified or contained within EVs. Further
evaluation is required for both the confirmation that EVs carry these variants and that the pre-
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enrichment of EVs improves these assays' sensitivity. This study was unable to assess this, as
only two patients positive for splicing variants had sufficient plasma available for EV isolation.
The presence of cancer-related splicing variants in tumour-derived EVs has been described
previously [351, 352]. The detection of splicing variants contained within EVs as biomarkers
has been pioneered in prostate cancer through screening for AR-V7 variants in plasma EVderived RNA [260, 263]. Splicing variants of AR, such as AR-V7 and AR-V9, have been found
to be significantly higher in hormone refractory prostate cancer and is associated with poor
clinical outcomes [262]. More recently, Fettke et al. showed that the presence of AR splice
variants in plasma derived RNA, together with other AR genetic aberrations, is associated with
poor outcomes of metastatic castration-resistant prostate cancer patients on available drug
treatments. Supported by these prostate cancer studies, the findings in Chapter 2 demonstrate
a new method to detect BRAF splicing events, underscoring new information that can be
provided through RNA analyses utilising non-invasive approaches.
The establishment that EVs can carry mediators of resistance, led to the investigation of EVs
as a transferrer of drug resistance between melanoma cells in Chapter 3. Transfer of resistance
by EVs in other cancers has widely been attributed to the movement of the multidrug resistance
mediator P-glycoprotein [353, 354]. Further studies have shown the transfer by EVs of different
types of mediators in the form of proteins and RNA species [284, 285, 287, 288, 291-294].
Previously, Vella et al. demonstrated that EVs can mediate resistance to BRAFi in melanoma
by delivering the RTK PDGFRβ [206]. As discussed in Chapter 1, melanoma has multiple
mechanisms to overcome BRAF inhibition. Thus, we sought to expand and evaluate the
capacity of EVs to transfer other resistant mediators for their capabilities in preventing cell
death. The work presented in Chapter 3 utilised the parental cell line SK-Mel-28 along, with
the three resistant derivatives BR2, BR4 and BR9, to evaluate the ability of these resistant lines
to transfer materials that can instigate BRAFi/MEKi resistance in-vitro. Preliminary work
determined that the mixture of parental cells with BR2 or BR9 improved the survival of the
sensitive cells. Minor growth benefits were observed when providing EVs to sensitive cells.
However, no protection from MAPK pathway inhibition was offered by transferring EVs from
resistant cells.
Given the complexities of the experimental models to evaluate the transfer of resistance,
several factors could have influenced the outcomes of the study. As discussed in Chapter 3,
multiple conditions should be altered to re-assess the abilities of EVs as a resistance mediator.
For example, high concentrations of the BRAFi may exceed the equimolar balance required
for protection that resistant derived EVs could provide. Thus, analysis of a broader range of
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concentrations need to be evaluated in the future. Moreover, additional effects of resistant cellderived EVs over other proliferative pathways, such as PI3K-AKT should have been evaluated
to discard MAPK independent resistance. Furthermore, the dynamics required to achieve a
drug resistant effect are not truly known, and it may be a requirement that a continuous delivery
of EVs is essential to sustain resistance. In addition, the dosage of EVs may be insufficient to
propagate resistance throughout the sensitive cells.
Numerous landmark studies have revealed the potential of EVs as predictors of patient
outcomes. The primary focus within EVs has been the possibility of profiling circulating RNA
species. Few studies have assessed plasma-derived EV mRNA from cancer patients, with most
studies focusing on miRNA profiling [256-258, 260, 313, 351, 355]. Within this thesis, Chapter
2 demonstrated the capability of isolating RNA from plasma EVs, using a column-based
method (exoEasy kit), and showed the presence of tumour-derived RNA species through the
detection of mutant BRAF and BRAF splicing variants. The work described in Chapter 4 built
on this research to evaluate the predictive value of plasma-derived EV-mRNA from late-stage
melanoma patients commencing immunotherapy with pembrolizumab.
Circulating EV transcriptome profiling determined a set of genes upregulated in patients that
respond to immune checkpoint inhibitors. Pathway analysis established that these genes were
involved in immune-related process, particularly concerning B-cells.
The identification of genes relating to activated B cells in circulating EVs as a biomarker of
response was revealing, as the role of B cells in the response to ICI has been only recently
established [322, 323, 327]. The density of B cells within TLS correlates with protective
immunity, and provide clinical benefit from immunotherapy for patients with lung cancer and
sarcoma [324, 338]. Moreover, an increased presence of TLS have profound long-term benefits
to overall patient survival in lung cancer [356]. Thus, the potential of the B-cell associated,
EV-derived gene sets identified in this study to predict response to pembrolizumab is an
exciting finding. Clinically no circulating markers are used to identify melanoma patients who
will respond or fail immune checkpoint inhibition. Although an excellent prospect, further
validation work is essential to confirm this panel of markers before it can be used clinically.
Notably, this pilot study only included 17 patients treated with pembrolizumab and primarily
consisted of patients responding to therapy patients. Only 35% of the cohort showed no
response, compared to the 61-66% observed in other clinical studies [107, 111]. Thus, this bias
may have affected the genes identified in our analysis, due to non-responders being poorly
represented. This underscores the need for validation in larger studies. Moreover, this study
only included patients treated with pembrolizumab as first-line therapy. However, melanoma
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patients who are BRAF mutant may be treated with targeted therapy as first line treatment,
potentially altering the tumour prior to intervention with ICI. As shown for other circulating
biomarkers, prior treatment with BRAFi undermines the prognostic value of ctDNA [341].
Thus, further study is needed to evaluate the set of genes identified here in patients receiving
immunotherapy as a second line treatment to determine its broader applications.
Early works established the ability of EVs to carry major histocompatibility complexes
(MHCs) within intestinal epithelial cell derived EVs [357], and within dendritic cell derived
EVs [358, 359]. The ability to detect immune specific genes either related to TLS or an
activated immune signature that can predict therapeutic outcomes is an exciting development.
The non-cancer specific nature of these genes and the extended role of TLS in cancer survival
and response to immunotherapy, suggests that the set of genes identified here may serve as a
general indicator of response across different cancers treated with immune checkpoint
inhibitors. Extended analysis of larger patient cohorts beyond melanoma, as well as within
melanoma treated with other ICI modalities will be critical for validation.

Concluding remarks
Overall, this thesis provides and demonstrates innovative approaches in applying the utility of
extracellular vesicles within the context of melanoma. EVs are an expanding role within the
realm of both the liquid biopsy space and within the therapeutic production space.
Key methodologies have been developed based on current literature to provide a preliminary
investigation into the role of EVs as resistance mediators. Although the works presented here
are not conclusive to prove the potential actions that EVs have in fostering resistance statuses,
they provide a foundation of which further work can build upon to overcome the limitations
within the study.
Utilising a robust method for EV-RNA isolation and characterisation, this work generated an
interesting set of EV associated transcripts that can differentiate melanoma patients responding
from non-responding to ICI. Historically the search for such a set of markers has been
controversial in their applicability. This pilot study should now be expanded to include other
immunotherapy types within melanoma and potentially include other cancers that also benefit
from immunotherapy.
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